Anthracycline derivative linker reagents, antibody-drug conjugates and methods
Anthracycline-linker reagents conjugated with antibodies form ADCs that address the limitations of anthracycline derivatives by improving tumor targeting and pharmacokinetics, achieving effective cancer treatment with reduced side effects.
Patent Information
- Application Number
- JP2024527365
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-10
- Filing Date
- 2022-11-04
- Publication Date
- 2024-11-21
AI Technical Summary
Anthracycline derivatives, despite their cytotoxic activity, face limitations in clinical use due to inadequate tumor accumulation, cardiotoxicity, prolonged infusion time, resistance in cancer cells, and dose-related side effects such as diarrhea and myelosuppression, necessitating improved delivery systems.
Development of anthracycline-linker reagents covalently attached to antibodies, forming antibody-drug conjugates (ADCs) that enhance tumor targeting and modify pharmacokinetic properties, with a linker system that allows controlled release of the cytotoxic payload.
The ADCs exhibit enhanced cytotoxic activity and a favorable safety profile, effectively inhibiting tumor growth with reduced off-target toxicity, demonstrating potential in cancer treatment.
Smart Images

Figure 2024543381000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention provides anthracycline-linker reagents for the preparation of therapeutic antibody-drug conjugate (ADC) compounds.
[0002] The present invention also provides therapeutic antibody-drug conjugate (ADC) compounds containing an anthracycline drug moiety that have biological activity against cancer cells, which can inhibit tumor growth in mammals and may be useful in the treatment of human cancer patients.
[0003] Aspects of the invention include methods for making, preparing, synthesizing, conjugating, and purifying drug-linker reagents and antibody-drug conjugate compounds. [Background technology]
[0004] Anthracyclines are antibiotic compounds that exhibit cytotoxic activity. Several studies have shown that anthracyclines can act to kill cells by several different mechanisms, including: 1) intercalation with cellular DNA, thereby inhibiting DNA-dependent nucleic acid synthesis; 2) generating free radicals that then react with cellular macromolecules and cause damage to the cell; or 3) interaction with cell membranes (see, for example, C. Peterson et al., "Transport and storage of Anthracycline in experimental systems and human leukemia" in Anthracycline Antibiotics in Cancer Therapy (1982), pp. 132-146 and N. R. Bachur, "Free Radical Damage" id. pp. 97-102). Due to their cytotoxic activity, anthracyclines have been used to treat a number of cancers, including leukemia, breast cancer, lung cancer, ovarian cancer, and sarcoma (see, for example, PH-Wiernik in Anthracycline: Current Status And New Developments (1980), p. 11). Commonly used anthracyclines include doxorubicin, epirubicin, idarubicin and daunomycin.
[0005] Morpholino analogs of doxorubicin and daunorubicin formed by cyclization on the glycosidic amino group have higher potency (Acton et al. (1984) J. Med. Chem. 638-645, WO 9802446, US 4464529, US 4672057, US 5304687).
[0006] Although these compounds may be useful in the treatment of neoplasia and other disease states in which selected cell populations are sought to be eliminated, their therapeutic efficacy is often limited by the dose-dependent toxicity associated with their administration.
[0007] Limitations in the clinical use of anthracycline derivatives include inappropriate accumulation in tumors, cardiotoxicity, prolonged infusion times, resistance in cancer cells that overexpress membrane transporters, and dose-limiting side effects such as diarrhea and bone marrow suppression (Int. J. Nanomedicine, 2007, 2(4), 567-83; Med. Sci. Monit. 2000, 6(2); Adriamycin Review, pp123-131; Mediokon, Belgium, European Press, 1975; Ann Intern Med. 1982, 96(2):133-139).
[0008] Drug conjugation of cytotoxic drugs to molecules that can vehicle the drug and thus improve tumor targeting or modify its pharmacokinetic properties is one of the strategies that has been pursued to solve the above problems (Xie et al. (2006) Expert, Opin. Biol. Ther. 6(3):281-291; Kovtun et al. (2006) Cancer Res. 66(6):3214-3121).
[0009] Different examples of conjugation of cytotoxic drugs (payloads) with proteins, peptides, aptamers, polymers or nanoparticles have been reported that allow better targeted delivery, improve solubility and in some cases improve other pharmacokinetic properties such as increasing the drug half-life or local concentration, improving drug performance, etc. In effect, the resulting conjugates have improved properties in terms of solubility, cell permeability, in vivo therapeutic window, controlled release, ability to reach the target, etc. due to the nature of the specific molecule conjugated with the cytotoxic agent.
[0010] In this anticipation, the conjugation of antibodies to cytotoxic agents, thus generating antibody drug conjugates (ADCs), is one of the emerging approaches for the discovery of novel drugs.
[0011] This approach incorporates the antibody specificity and cell-killing activity of chemically conjugated highly cytotoxic drugs. The antibody in the ADC structure acts as a targeting agent and nanoscale carrier to deliver therapeutic doses of the cytotoxic cargo to the desired tumor cells.
[0012] Anthracycline derivative conjugates to antibodies are disclosed, for example, in International Patent Applications Nos. 2009 / 099741 and 2010 / 009124. Immunoconjugates and prodrugs of daunorubicin and doxorubicin have been prepared and studied (Kratz et al. (2006) Current Med. Chem. 13:477-523; Jeffrey et al. (2006) Bioorganic & Med. Chem. Letters 16:358-362). The antibody-drug conjugate BR96-doxorubicin specifically reacts with the tumor-associated antigen Lewis-Y and has been evaluated in phase I and phase II studies (Saleh et al. (2000) J. Clin. Oncology 18:2282-2292; Ajani et al. (2000) Cancer Jour. 6:78-81; Tolcher et al. (1999) J. Clin. Oncology 17:478-484).
[0013] However, ADCs as potential targeted delivery systems must go through all obstacles including blood circulation, antigen binding, internalization, payload release, and final payload action. Off-target release of cytotoxic payloads has been recognized as one of the problems that cause increased toxicity of such drugs and thus hinder their clinical development (Avicenna J Med Biotechnol. 2019 Jan-Mar, 11(1):3-23. and KRKozak(2020)).
[0014] For this reason, there is an increasing demand for the development of functionalized cytotoxic agents suitable to be conjugated with different types of molecules that exhibit a good balance between efficacy and toxicity. [Prior art documents] [Patent documents]
[0015] [Patent Document 1] WO 98 / 02446 [Patent Document 2] U.S. Patent No. 4,464,529 [Patent Document 3] U.S. Patent No. 4,672,057 [Patent Document 4] U.S. Patent No. 5,304,687 [Patent Document 5] WO 2009 / 099741 [Patent Document 6] WO 2010 / 009124 [Non-Patent Document]
[0016] [Non-Patent Document 1] C. Peterson et al., "Transport and storage of Anthracycline in experimental systems and human leukemia" in Anthracycline Antibiotics in Cancer Therapy (1982), pp. 132 - 146 [Non-Patent Document 2] N. R. Bachur, "Free Radical Damage" id. pp. 97 - 102 [Non-Patent Document 3] P. H - Wiernik in Anthracycline: Current Status And New Developments (1980), p. 11 [Non-Patent Document 4] Acton et al. (1984) J. Med. Chem. 638 - 645 [Non-Patent Document 5] Int. J. Nanomedicine, 2007; 2(4): 567 - 83 [Non-Patent Document 6] Med. Sci. Monit. 2000; 6(2)
Non-Patent Document 7
Non-Patent Document 8
Non-Patent Document 9
Non-Patent Document 10
Non-Patent Document 11
Non-Patent Document 12
Non-Patent Document 13
Non-Patent Document 14
Non-Patent Document 15
Non-Patent Document 16
Summary of the Invention
[0017] The inventors have now found that functionalized anthracycline derivatives that exhibit moderate cytotoxic activity when tested by themselves in biological assays, when conjugated with antibodies, thus forming the corresponding ADCs, unexpectedly exhibit very good cytotoxic activity and a very good safety profile. Thus, the novel ADCs may be useful for treating cancer and other pathologies.
[0018] <Definition> An "anthracycline drug" or "anthracycline derivative drug" is a compound of formula (II) that has cytotoxic activity.
[0019] An "anthracycline-linker reagent" (Ant-L) is a compound that contains an anthracycline drug or an anthracycline derivative drug covalently attached to a linker moiety that contains a reactive functional group. Anthracycline-linker reagents can be conveniently used to prepare anthracycline-drug conjugates by reaction with a carrier moiety.
[0020] An "anthracycline derivative conjugate" or "anthracycline-drug conjugate" is a compound comprised of an anthracycline derivative drug covalently attached via a linker to a carrier moiety, including an antibody, protein, or peptide. Anthracycline derivative conjugate compounds include antibody-drug conjugate (ADC) compounds.
[0021] A "linker" or "link" is a chemical moiety that comprises a covalent bond or a chain of atoms covalently attached to an "anthracycline drug" or an "anthracycline-drug derivative" (Ant) to form an anthracycline-linker reagent (Ant-L).
[0022] The term "antibody" herein is used in the broadest sense and specifically includes monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired biological activity (Miller et al. (2003) Jour. of Immunology 170:4854-4861). Antibodies may be murine, human, humanized, chimeric, or derived from other species. Antibodies are proteins produced by the immune system that can recognize and bind to specific antigens (Janeway, C., Travers, P., Walport, M., Shlomchik (2001) Immuno Biology, 5th ed., Garland Publishing, New York). A target antigen generally has multiple binding sites, also called epitopes, that are recognized by CDRs on multiple antibodies. Each antibody that specifically binds to a different epitope has a different structure. Thus, one antigen may have multiple corresponding antibodies. Antibodies include full-length immunoglobulin molecules or immunologically active portions of full-length immunoglobulin molecules, i.e., molecules that contain an antigen-binding site that immunospecifically binds to an antigen of a target of interest or portions thereof, such targets including, but not limited to, cancer cells or cells that produce autoimmune antibodies associated with autoimmune diseases. Immunoglobulins can be of any type (e.g., IgG, IgE, IgM, IgD, and IgA), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) or subclass of immunoglobulin molecule. Immunoglobulins can be from any species, including human, murine, or rabbit origin.
[0023] An "ErbB receptor" is a receptor protein tyrosine kinase that belongs to the ErbB receptor family, which are important mediators of cell proliferation, differentiation and survival. The ErbB receptor family includes epidermal growth factor receptor (EGFR, ErbB1, HER1), HER2 (ErbB2 or p185 neuErbB receptors include four distinct members, including EGFR (ErbB1), HER3 (ErbB3), and HER4 (ErbB4 or tyro2). ErbB receptors generally include an extracellular domain capable of binding to ErbB ligands, a lipophilic transmembrane domain, a conserved intracellular tyrosine kinase domain, and a carboxyl-terminal signaling domain with several tyrosine residues that can be phosphorylated. An ErbB receptor can be a "native sequence" ErbB receptor or an "amino acid sequence variant" thereof. An ErbB receptor can be a native sequence human ErbB receptor. Thus, a "member of the ErbB receptor family" is EGFR (ErbB1), ErbB2, ErbB3, ErbB4, or any other ErbB receptor now known or identified in the future. Sequence identity screening has led to the identification of two other ErbB receptor family members, namely ErbB3 (US5183884, US5480968, Kraus et al. (1989) PNAS (USA) 86:9193-9197) and ErbB4 (EP599274, Plowman et al. (1993) Proc. Natl. Acad. Sci. USA, 90:1746-1750, Plowman et al. (1993) Nature 366:473-475). Both of these receptors show increased expression in at least some breast cancer cell lines. Anti-ErbB2 antibodies have been characterized (US5677171, US5821337, US6054297, US6165464, US6407213, US6719971, US6800738).
[0024] "Carrier moieties" are derived from polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin. Carrier moieties are suitable for conjugation with anthracycline-drug reagents of formula (I). The carrier moiety may be derived from polyclonal antibodies raised against tumor-associated antigens or monoclonal antibodies which bind to antigens preferentially or selectively expressed on tumor cell populations, or from natural or recombinant peptides or proteins or growth factors which preferentially or selectively bind to tumor cells, or from natural or synthetic polymeric carriers, e.g. polylysine, polyglutamic acid, polyaspartic acid and analogs and derivatives thereof, or for example dextran or other polymeric carbohydrate analogs and derivatives thereof, or synthetic copolymers such as those derived from N-(2-hydroxypropyl)methacrylamide (HPMA) (see J. Kopecek, Macromolecules. H. Benoit & P. Rempp, eds.: 505-520 (1982) Pergamon Press. Oxford, England) or poly(amino acid) copolymers such as poly(GluNa, Ala, Tyr), useful as targeting drug-carriers for lung tissue R (Duncan et al., Journal of Bioactive and Compatible Polymers, Vol. 4, July 1989).
[0025] The term payload, as used herein, refers to any chemical structure derived from the chemical or biochemical degradation of an antibody drug conjugate (ADC) containing an anthracycline residue that has cytotoxic activity. Particularly preferred is a payload of formula (II):
[0026] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies constituting the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific and directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations, which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies used in accordance with the present invention may be produced by the hybridoma method first described by Kohler et al. (1975) Nature 256:495, or may be produced by recombinant DNA methods (see US4816567). Monoclonal antibodies can also be isolated from phage antibody libraries using the techniques described in Clackson et al. (1991) Nature, 352:624-628; Marks et al. (1991) J. Mol. Biol., 222:581-597.
[0027] Monoclonal antibodies herein specifically include "chimeric" antibodies, in which a portion of the heavy and / or light chains are identical or homologous to corresponding sequences in antibodies from a particular species or belonging to a particular antibody class or subclass, and the remainder of the chains are identical or homologous to corresponding sequences in antibodies from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (US4816567 and Morrison et al. (1984) Proc. Natl. Acad. Sci. USA, 81:6851-6855). Chimeric antibodies include "primatized" antibodies that contain variable domain antigen-binding sequences derived from a non-human primate (e.g., Old World Monkey or Ape) and human constant region sequences.
[0028] An "antibody fragment" comprises a portion of a full-length antibody, generally the antigen-binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments, diabodies, linear antibodies, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, CDRs (complementarity determining regions), and epitope-binding fragments of any of the above that immunospecifically bind to cancer cell antigens, viral antigens, or microbial antigens, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments.
[0029] The term "amino acid side chain" includes those groups found below: (i) naturally occurring amino acids, such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; (ii) minor amino acids, such as ornithine and citrulline; (iii) unnatural D-amino acids, β-amino acids, synthetic analogs and derivatives of naturally occurring amino acids; and (iv) all enantiomers, diastereomers, isomerically enriched, isotopically labeled, protected forms, and racemic mixtures thereof.
[0030] The term "straight chain or branched C1-C6 alkyl" intends any of the groups such as, for example, methyl, ethyl, n-propyl, n-butyl, n-pentyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl.
[0031] The term "linear or branched C1-C4 hydroxyalkyl" intends any of the groups such as, for example, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 4-hydroxybutyl, 3-hydroxybutyl, 2-hydroxybutyl.
[0032] The term "halogen" intends fluorine, chlorine, bromine or iodine.
[0033] The term "straight chain or branched C1-C4 haloalkyl" intends any of the C1-C4 alkyl groups as defined above that is substituted by one or more halogen atoms (such as, for example, trifluoromethyl and trifluoroethyl).
[0034] The term "heterocycle" as used herein refers to a saturated or unsaturated non-aromatic 5- to 7-membered carbocyclic ring in which 1 to 3 carbon atoms are replaced by heteroatoms selected from nitrogen, oxygen and sulfur, which may be directly bonded to each other, the nitrogen and sulfur may be optionally oxidized, and the nitrogen may be optionally quaternized or may carry a substituent. Non-limiting examples of heterocyclic groups are, for example, piperidinyl, piperazinyl, oxazolidinyl, 4-methylpiperazinyl, 4-ethylpiperazinyl, diazepinyl, and the like.
[0035] The term "aryl" as used herein refers to a carbocyclic hydrocarbon having one to two ring moieties fused or linked together by a single bond, where at least one of the rings is aromatic. Examples of aryl groups according to the present invention are, for example, phenyl, biphenyl, α- or β-naphthyl, dihydronaphthyl, and the like.
[0036] The term "carbocycle" refers to a 3- to 7-membered all-carbon monocyclic ring, which may contain one or more double bonds, but does not have a completely conjugated pi-electron system.
[0037] Examples of carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexanyl, cyclohexenyl, and cyclohexadienyl.
[0038] The term "leaving group" refers to a group that can be replaced by another group in a substitution reaction. Such leaving groups are well known in the art and examples include halides (fluorides, chlorides, bromides and iodides), azides, sulfonates (e.g., optionally substituted C1-C6 alkanesulfonates, such as methanesulfonate and trifluoromethanesulfonate, or optionally substituted C7-C8 alkanesulfonates, such as methylsulfonate and methylsulfonate, or optionally substituted C8-C9 alkanesulfonates, such as methylsulfonate and methylsulfonate, or optionally substituted C9-C10 alkanesulfonates, such as methylsulfonate and methylsulfonate, or optionally substituted C1-C6 ...12 Leaving groups include, but are not limited to, alkylbenzenesulfonates (e.g., p-toluenesulfonate), succinimide-N-oxide, p-nitrophenoxide, pentafluorophenoxide, tetrafluorophenoxide, carboxylates, aminocarboxylates (carbamates), and alkoxycarboxylates (carbonates). For substitution at a saturated carbon, halides and sulfonates are preferred leaving groups. For substitution at a carbonyl carbon, halides, succinimide-N-oxide, p-nitrophenoxide, pentafluorophenoxide, tetrafluorophenoxide, carboxylates, or alkoxycarboxylates (carbonates) can be used, for example, as leaving groups. The term "leaving group" also refers to a group that is eliminated as a result of an elimination reaction, for example, an electronic cascade reaction or a spirocyclization reaction. In this case, halides, sulfonates, azides, aminocarboxylates (carbamates), or alkoxycarboxylates (carbonates) can be used as leaving groups.
[0039] It is known to those skilled in the art that the conversion of a chemical functional group into another may require that one or more reactive centers in the compound containing such functional group must be protected in order to avoid undesired side reactions. The protection of such reactive centers, and the subsequent deprotection at the end of the synthetic transformation, can be achieved according to standard procedures described in the literature (see, for example, Green, Theodora W. and Wuts, Peter GM - Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons Inc., New York (NY), 1999).
[0040] Thus, the term "protecting group" refers to groups used to protect such reactive centers in chemical synthesis, such as hydroxyl (-OH), amino (-NH), thiol (-SH), carbonyl (-C=O), carboxyl (-COOH) groups. Examples of protecting groups are those reported in the literature (see, for example, ibidem).
[0041] The term "nitrogen protecting group" refers to a group that forms carbamates, amides, cyclic imides, N-alkyl and N-arylamines with the nitrogen atom. Such protecting groups are well known in the art (see, for example, ibidem). Non-limiting examples of carbamate protecting groups are, for example, methyl and ethyl carbamates, 9-fluorenylmethyl carbamate (Fmoc), 2,2,2-trichloroethyl carbamate (Troc), t-butyl carbamate (Boc), vinyl carbamate (Voc), allyl carbamate (Alloc), benzyl carbamate (Cbz), p-nitrobenzyl, and the like. Non-limiting examples of amides are, for example, N-trichloroacetamide, N-trifluoroacetamide (TFA), and the like. Non-limiting examples of cyclic imide protecting groups are, for example, N-phthalimide, N-dithiasuccinoyl imide (Dts), and the like. Non-limiting examples of N-alkyl and N-aryl protecting groups include, for example, N-allylamine, N-benzylamine, and the like.
[0042] The term "hydroxyl protecting group" refers to a group that forms an ether, ester, cyclic acetal or ketal with an oxygen atom. Such protecting groups are well known in the art (see, for example, ibidem). Non-limiting examples of ether protecting groups are, for example, alkyl ethers and benzyl ethers, such as methoxymethyl ether (MOM-OR), tetrahydropyranyl ether (THP-OR), allyl ether (allyl-OR), benzyl ether (Bn-OR), triphenylmethyl ether (Tr-OR), or silyl ethers, such as trimethylsilyl ether (TMS-OR), t-butyldimethylsilyl ether (TBS-OR or TBDMS-OR), t-butyldiphenylsilyl ether (TBDPS-OR), diphenylmethylsilyl ether (DPMS-OR), and the like. Non-limiting examples of ester protecting groups are, for example, trifluoroacetate, benzoate (Bz-OR), and carbonates, such as ethyl carbonate, and the like. Non-limiting examples of cyclic acetal or ketal protecting groups include, for example, methylene acetal, ethylidene acetal, methoxymethylene acetal, and the like.
[0043] The term "active ester" refers to a functional group in which the alkoxy group of the ester moiety is a good leaving group. Examples of such alkoxy groups include, but are not limited to, succinimide-N-oxide (NHS ester), p-nitrophenoxide, pentafluorophenoxide, tetrafluorophenoxide, 1-hydroxybenzotriazole and 1-hydroxy-7-azabenzotriazole, and groups with equivalent leaving ability. Unsubstituted alkyl-based alkoxy groups such as methoxy, ethoxy, isopropoxy and t-butoxy are not considered good leaving groups, and methyl, ethyl, isopropyl, and t-butyl esters are not considered active esters.
[0044] The term "electron-withdrawing group" refers to an atomic group that draws electron density from adjacent atoms toward itself, usually by resonance or inductive effects. Non-limiting examples are halogens, trifluoromethyl groups, nitro (NO2) groups, and nitriles (CN).
[0045] The term "nucleophile" refers to a molecule that has a nucleophilic group. The term "nucleophilic group" refers to a species that donates an electron pair to an electrophilic group to form a chemical bond in a chemical reaction. Examples of such nucleophilic groups include, but are not limited to, halogens, amines, nitrites, azides, hydroxyls, alkoxide anions, carboxylate anions, thiols, thiolates, and the like.
[0046] The term "electrophilic group" refers to a species that accepts an electron pair from a nucleophilic group to form a chemical bond in a chemical reaction. Examples of such electrophilic groups include, but are not limited to, esters, aldehydes, amides, ketones, etc.
[0047] The term "unnatural D-amino acid" refers to the D-stereoisomers (or L-stereoisomers) of the naturally occurring amino acids. [Brief description of the drawings]
[0048] [Figure 1] FIG. 1 shows in vivo activity data of an ADC compound of the invention (Iaiv) against HCC1954 xenograft model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0049] The first object of the present invention is to An anthracycline-linker reagent of formula (I) comprising an anthracycline drug (Ant) covalently attached to a linker (L), or a pharma- ceutically acceptable salt thereof,
[0050] [ka] During the ceremony, Ant is an anthracycline drug moiety of formula (II),
[0051] [ka] During the ceremony, X is O or NH; A is a heterocycle (Het) or a carbocycle (Cb) selected from the group consisting of (IIIa) to (IIIe);
[0052] [ka] [In the formula, R is independently hydrogen or linear or branched (C1-C6) alkyl; n is an integer from 0 to 6, L is a linker of formula (VI),
[0053] [ka] During the ceremony, W is independently absent or an immolative system selected from the group consisting of (Va)-(Vc);
[0054] [ka] During the ceremony, R1 and R2 are each independently hydrogen, halogen, methyl, ethyl, or linear or branched C1-C4 hydroxyalkyl; PE is independently a dipeptide or tripeptide moiety consisting of absent or any combination of naturally occurring L-amino acids and non-naturally occurring D-amino acids; RM is a reactive moiety selected from the group consisting of (VIa)-(VIc);
[0055] [ka] During the ceremony, R3 and R4 are each independently hydrogen, halogen, methyl, ethyl, linear or branched C1-C4 hydroxyalkyl, linear or branched C1-C4 haloalkyl, or R3 and R4 together form a 3- to 6-membered carbocyclic ring; R5 is hydrogen, C1-C3 alkyl, or an electron-withdrawing group containing a NO2 group or a CN group; and r is an integer from 0 to 7.
[0056] In the compound of formula (I), the self-immolative system W tethers in a stable manner the moiety A of the anthracycline derivative drug of formula (II) to the PE-RM residue, or to the RM moiety if PE is absent.
[0057] The bond between RM and the linking atom of the group PE, or W when PE is absent, or A when W and PE are both absent, may form an amide, ester or thioester group.
[0058] Preferred anthracycline-linker reagents of formula (I) are the following compounds: wherein A is a heterocyclic or carbocyclic group selected from the group consisting of:
[0059] [ka] During the ceremony, R is a linear or branched (C1-C6) alkyl; L is a linker of formula (VI) where W is a group (Va') or (Vb');
[0060] [ka]
[0061] PE is a dipeptide or tripeptide moiety consisting of any combination of the following amino acids: glycine, alanine, leucine, valine, citrulline, and phenylalanine, the C-terminal amino acid residue being linked to W and the N-terminal amino acid residue being linked to RM; RM is a group selected from (VIa) to (VIc),
[0062] [ka] During the ceremony, R3, R4 and R5 are hydrogen; Preferably, r is an integer of 3 to 5.
[0063] More preferred anthracycline-linker reagents of formula (I) are the following compounds: wherein A is a heterocyclic group selected from the group consisting of (IIIa'), (IIIa"), (IIIb') and (IIIc'); During the ceremony, R is a straight chain (C1-C6) alkyl; W is a group (Va') or (Vb'), PE is a dipeptide or tripeptide selected from valine-alanine and valine-citrulline, During the ceremony, the C-terminal amino acid residue is linked to W and the N-terminal amino acid residue is linked to RM; RM is a reactive moiety selected from groups (VIa)-(VIc), During the ceremony, R3, R4 and R5 are hydrogen; r is an integer from 3 to 5.
[0064] Other more preferred anthracycline-linker reagents of formula (I) are the following compounds: In the formula, A is a heterocyclic group selected from the group consisting of (IIIa'), (IIIa"), (IIIb') and (IIIc'); During the ceremony, R is a straight chain (C1-C6) alkyl; L is a linker selected from the group consisting of (IVa)-(IVc),
[0065] [ka] During the ceremony, r is an integer from 3 to 5.
[0066] Preferred specific anthracycline-linker reagent compounds of formula (I) or pharma- ceutically acceptable salts thereof are those listed below: [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate (compound 1),
[0067] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate (compound 2);
[0068] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate (compound 3),
[0069] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate (compound 4),
[0070] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate (compound 5),
[0071] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate (compound 6),
[0072] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate (compound 7),
[0073] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate (compound 8),
[0074] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate (compound 9),
[0075] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate (compound 10),
[0076] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate (compound 11),
[0077] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate (compound 12),
[0078] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-1,4-diazepane-1-carboxylate (compound 13),
[0079] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-1,4-diazepane-1-carboxylate (compound 14),
[0080] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-1,4-diazepane-1-carboxylate (Chemical formula 15) and
[0081] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-1,4-diazepane-1-carboxylate (compound 16).
[0082] In the anthracycline-linker reagent of formula (I), one or more of the bonds between Ant and the linker L, or the covalent bonds between W and PE or PE and RM of the linker itself, may be stable outside the cell, i.e., extracellularly, or may be cleavable by enzymatic activity, hydrolysis or other metabolic conditions, thereby releasing the anthracycline payload, which is a compound that exhibits cytotoxic activity.
[0083] It is clear to one skilled in the art that upon bond cleavage, the valence of the atoms involved is restored with a hydrogen atom or an OH group depending on the cleavage type reaction. Thus, without limiting the scope of the invention, upon cleavage of the Ant-L bond in a compound of formula (I), the released anthracycline payload is a compound of formula (II), wherein: A is a heterocyclic or carbocyclic group selected from the group consisting of:
[0084] [ka] During the ceremony, Het, Cb, R and n are as defined above.
[0085] An anthracycline-linker reagent of formula (I) is a compound that contains a reactive functional group (RM moiety) that can react with a carrier moiety to form an anthracycline drug conjugate. When the carrier moiety is an antibody (Ab), the conjugate is an antibody-drug conjugate (ADC).
[0086] A second object of the present invention is to provide an antibody-drug conjugate (ADC) of formula (Ia):
[0087] [ka] During the ceremony, Ab includes any entity, type or class of antibody that binds to, reactively associates with, or forms a complex with a receptor, antigen or other receptor moiety associated with a given target cell population; m (drug loading) is an integer from 1 to 8; Ant-L is an anthracycline-linker reagent of formula (I), where the RM portion of the linker L reacts with a cysteine thiol or an amine, such as the N-terminus or an amino acid side chain, such as lysine, of an antibody (Ab), thus forming an antibody drug conjugate of formula (Ia). For clarity, the linkage between RM and the antibody Ab, thus forming the antibody drug conjugate of formula (Ia), is reported below:
[0088] [ka] During the ceremony, The dashed lines represent the points of attachment of the RM residue to PE, or to W if PE is absent, or to A of the anthracycline drug of formula (II) if both W and PE are absent; R3 and R4 are as defined above; r is an integer from 0 to 7; m is as defined above.
[0089] The ratio of anthracycline drug to antibody, or drug loading, is represented by m of the compounds of formula (Ia). Drug loading values m range from 1 to 8. Compounds of formula (Ia) include all mixtures of variously loaded and conjugated antibody-drug conjugates in which 1, 2, 3, 4, 5, 6, 7 or 8 drug moieties are covalently attached to the antibody, preferably m is 1, 2, 3 or 4.
[0090] A preferred ADC of formula (Ia) is the following compound: where Ant-L is an anthracycline-linker reagent selected from compounds 1-16; m and Ab are as defined above.
[0091] A more preferred ADC of formula (Ia) is the following compound: wherein Ab is an antibody that binds to one or more tumor-associated ErbB2 antigens or cell surface ErbB2 receptors; Ant-L and m are as defined above.
[0092] Another more preferred ADC of formula (Ia) is the following compound: In the formula, Ab is a compound that is trastuzumab (TRZ).
[0093] The most preferred ADC of formula (Ia) is the compound (Ia I )~(Ia XVI ) is a compound selected from the group consisting of:
[0094] [ka] TIFF2024543381000016.tif226167TIFF2024543381000017.tif168166TIFF2024543381000018.tif220163TIFF2024543381000019.tif169165TIFF2024543381000020.tif218170TIFF2024543381000021.tif136170In the formula, m is an integer of 1 to 8. Preferably, m is an integer of 2 to 6.
[0095] The Ant-L bond and / or L-Ab bond and / or the covalent bond connecting the moieties W, PE and RM of the linker (L) may be stable outside the cell, i.e. extracellularly, or may be cleavable by enzymatic activity, hydrolysis or other metabolic conditions.
[0096] The linkage is preferably stable outside the cell. Prior to transport or delivery to the cell, the antibody-drug conjugate (ADC) is preferably stable and remains intact, i.e., the antibody remains attached to the drug moiety. The linker is stable outside the target cell and can be cleaved at some effective rate inside the cell. An effective linker (i) maintains the specific binding properties of the antibody, (ii) allows intracellular delivery of the conjugate or anthracycline payload, (iii) remains stable and intact, i.e., is not cleaved, until the conjugate is delivered or transported to its target site, and (iv) maintains the cytotoxic, cell-killing or cytostatic effect of the anthracycline payload. The stability of the ADC can be measured by standard analytical techniques, such as mass spectrometry, HPLC, and the separation / analysis technique LC / MS.
[0097] The ADCs of the invention as well as the anthracycline-drugs of formula (I) are novel compounds characterized in that they contain a moiety (A) encapsulating two secondary or tertiary amine functional groups that, among other parameters, greatly influence the polarity and solubility of the molecules and thus their pharmacokinetic properties. When non-specific release of the payload from the ADC occurs, as in the compounds of the invention, it can be speculated that the presence of a protonatable moiety on the payload structure may prevent passive diffusion of the released cytotoxic payload into the cells, thus reducing non-specific toxicity and improving the safety profile of the ADC.
[0098] The uniqueness of the novel (A) moiety in the structure of the ADCs significantly distinguishes the structures of the present invention from those of the prior art, both in terms of chemical structure and in terms of chemical and physical properties.
[0099] Drug Loading Drug loading is represented by m in the antibody-drug conjugate molecule of formula (Ia). Drug loading can range from 1 to 8 anthracycline drugs (Ant) per antibody (Ab), i.e., 1, 2, 3, 4, 5, 6, 7 or 8 anthracycline drug moieties are covalently attached to the antibody via a linker (L), preferably m can range from 2 to 6. The average number of anthracycline drugs per antibody in a preparation of ADC from a conjugation reaction can be characterized by conventional means such as mass spectrometry, ELISA assay, electrophoresis, and HPLC. The quantitative distribution of the ADC with respect to m can also be determined. The average value of m in a particular preparation of ADC can be determined by ELISA (Hamblett et al. (2004) Clin.Cancer Res.10:7063-7070, Sanderson et al. (2005) Clin.Cancer Res.11:843-852). However, the distribution of m(anthracycline drug) values is not distinguishable by antibody-antigen binding and detection limits of ELISA. Also, ELISA assays for detection of antibody-drug conjugates do not determine where on the antibody the anthracycline drug moiety is attached, e.g., to the heavy or light chain fragment, or to a particular amino acid residue. In some cases, separation, purification, and characterization of homogeneous ADCs with a particular value of m from ADCs with other drug loadings can be achieved by means such as reverse-phase HPLC or electrophoresis.
[0100] For some antibody-drug conjugates, m may be limited by the number of binding sites on the antibody. For example, an antibody may have only one or a few cysteine thiol groups, or only one or a few sufficiently reactive thiol groups through which a linker can be attached. Higher drug loading, for example m>6, may cause aggregation, insolubility, toxicity, or loss of cell permeability of certain antibody-drug conjugates.
[0101] Typically, less than the theoretical maximum drug moiety is conjugated to the antibody during the conjugation reaction. The antibody may contain many lysine residues that do not react with, for example, anthracycline-linker reagents (Ant-L). Only the most reactive lysine groups can react with amine-reactive linker reagents. Also, only the most reactive cysteine thiol groups can react with thiol-reactive linker reagents. In general, the antibody does not contain many free and reactive cysteine thiol groups (if any) that can be linked to the drug moiety. Most cysteine thiol residues in the antibody of the compound exist as disulfide bridges and must be reduced with a reducing agent such as dithiothreitol (DTT) or TCEP under partial or complete reducing conditions. In addition, the antibody must be subjected to denaturing conditions to expose reactive nucleophilic groups such as lysine or cysteine. The loading (drug / antibody ratio) of the ADC can be controlled in several different ways, including: (i) limiting the molar excess of the anthracycline-linker reagent (Ant-L); (ii) limiting the conjugation reaction time or temperature; and (iii) partial or limiting reducing conditions for cysteine thiol modification.
[0102] Cysteine amino acids can be engineered at reactive sites in antibodies and do not form intrachain or intermolecular disulfide bonds (US7521541). The engineered cysteine thiols can react with the anthracycline-linker reagents (Ant-L) of the present invention bearing thiol-reactive electrophilic groups, such as compounds of formula (VIa) or (VIb), to form cysteine engineered antibodies and ADCs bearing anthracycline derivative drug moieties. Thus, the location of the drug moiety can be designed, controlled, and known. The engineered cysteine thiol groups typically react with anthracycline-linker reagents in high yields, allowing for controlled drug loading. Engineering an IgG antibody to introduce a cysteine amino acid by substitution at a single site on the heavy or light chain results in two new cysteines on a symmetric antibody. Drug loading close to 2 and near homogeneity of the conjugation product ADC can be achieved.
[0103] When multiple nucleophilic or electrophilic groups on an antibody react with an anthracycline-linker reagent (Ant-L), the resulting product is a mixture of ADC compounds with a distribution of anthracycline drug moieties attached to the antibody, e.g., 1, 2, 3, etc. Liquid chromatography methods such as polymeric reversed phase (PLRP) and hydrophobic interaction (HIC) can separate compounds in a mixture by drug loading value. Although preparations of ADCs with a single drug loading value m can be isolated, these single loading value ADCs can still be heterogeneous mixtures because the drug moieties can be attached to different sites on the antibody via the linker.
[0104] Thus, the ADC compositions of the invention include mixtures of ADC compounds in which antibodies bear one or more anthracycline derivative drug moieties, and the anthracycline drug moieties can be attached to the antibody at various amino acid residues.
[0105] The conjugates of formula (Ia) of the present invention are useful therapeutic agents because they contain a cleavable bond that releases the anthracycline payload upon hydrolysis or "in vivo" enzymatic cleavage.
[0106] It is well known that malignant tumors have a higher glycolytic rate compared to normal tissues. This leads to an increased production of lactate, thus causing a decrease in pH in tumors (see HM Rauen et al., Z. Naturforsch, Teil B, 23 (1968) 1461). The present invention provides two levels of action specificity for the compounds, the first of which provides preferential localization of the conjugate in tumor tissues by antigen recognition, and the second of which provides preferential release of the drug in its active form in tumor tissues by preferential acidic cleavage. Without limiting the scope or usefulness of the compositions or methods of the present invention, the linkers described herein can be cleaved in vivo under local or systemic acidic conditions, thus separating the targeting antibody from the anthracycline payload.
[0107] The present invention also provides methods of synthesis of the anthracycline conjugates of formula (Ia) and anthracycline drug reagents (I), as well as their isomers, tautomers, hydrates, solvates, complexes, metabolites and N-oxides, prepared by a process consisting of standard synthetic transformations.
[0108] The present invention also provides the use of anthracycline-linker reagent compounds of formula (I) as synthetic intermediates for the preparation of antibody-drug conjugate compounds of formula (Ia).
[0109] The present invention also provides the use of anthracycline derivatives of formula (II) as synthetic intermediates for the preparation of anthracycline-linker reagent compounds of formula (I).
[0110] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a derivative of formula (Ia) as defined above or a pharma- ceutically acceptable salt thereof and at least one pharma- ceutically acceptable excipient, carrier or diluent.
[0111] The pharmaceutical composition containing the compound of the present invention is usually prepared according to conventional methods and administered in suitable pharmaceutical form.For example, solid oral forms can contain, together with active compound, diluents such as lactose, dextrose, saccharose, cellulose, corn starch or potato starch, lubricants such as silica, talc, stearic acid, magnesium stearate or calcium stearate, and / or polyethylene glycol, binders such as starch, gum arabic, gelatin, methylcellulose, carboxymethylcellulose or polyvinylpyrrolidone, disintegrants such as starch, alginic acid, alginate or sodium starch glycolate, effervescent mixtures, dyes, sweeteners, wetting agents such as lecithin, polysorbate, lauryl sulfate, and non-toxic and pharmacologically inactive substances generally used in pharmaceutical preparations.These pharmaceutical preparations can be produced in a known manner, for example by mixing, granulating, tableting, sugar-coating or film-coating process.
[0112] Liquid dispersions for oral administration may be, for example, syrups, emulsions and suspensions.By way of example, syrups may contain as carrier saccharose or saccharose with glycerin and / or mannitol and sorbitol.
[0113] Suspensions and emulsions may contain, as examples of carriers, natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol. Suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharma- ceutically acceptable carrier, such as sterile water, olive oil, ethyl oleate, glycols, such as propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride. Solutions for intravenous injection or infusion may contain sterile water as a carrier, or, preferably, they may be in the form of sterile, aqueous, isotonic, saline, or they may contain propylene glycol as a carrier. Suppositories may contain, together with the active compound, a pharma- ceutically acceptable carrier, such as cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
[0114] The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a derivative of formula (Ia) and one or more chemotherapeutic agents.
[0115] The present invention also provides pharmaceutical compositions comprising a therapeutically effective amount of a derivative of formula (Ia) in combination with known anti-cancer treatments (e.g., radiotherapy or chemotherapy regimens) in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g., COX-2 inhibitors), matrix metalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER2 agents, anti-EGFR agents, anti-angiogenic agents (e.g., angiogenesis inhibitors), farnesyltransferase inhibitors, ras-raf signaling pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.
[0116] In addition, the present invention provides a product comprising a derivative of formula (Ia) or a pharma- ceutically acceptable salt thereof as defined above, and one or more chemotherapeutic agents as a combined preparation for simultaneous, separate or sequential use in anti-cancer therapy.
[0117] If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharma- ceutical active agent(s) within their approved dosage range.
[0118] Compounds of formula (Ia) may be used sequentially with known anti-cancer agents when a combination formulation is inappropriate.
[0119] The compounds of formula (Ia) of the present invention suitable for administration to mammals, such as humans, may be administered by any of the usual routes, with dosage levels depending on the age, weight, condition of the patient and the route of administration.
[0120] For example, suitable dosages employed for intravenous administration of a compound of formula (Ia) may range from about 0.1 to about 10 mg / kg per daily dose. The compounds of the present invention can be administered in various dosage forms, for example orally, in the form of tablets, capsules, sugar-coated or film-coated tablets, liquid solutions or suspensions, rectally in the form of suppositories, parenterally, for example subcutaneously, intramuscularly, or by intravenous and / or intrathecal and / or intraspinal injection or infusion.
[0121] In yet another aspect, the present invention provides a derivative of formula (Ia) as defined above, or a pharma- ceutically acceptable salt thereof, for use as a medicament.
[0122] The present invention also provides a derivative of formula (Ia) as defined above for use in a method for the treatment of cancer, cell proliferation disorders and viral infections.
[0123] Preferably, the derivatives of formula (Ia) as defined above are useful in the treatment of cancers including, but not limited to, small cell lung cancer, carcinomas of the esophagus, gallbladder, ovary, pancreas, stomach, cervix, thyroid, bladder including prostate, breast, colon, kidney, liver, lung, and skin cancer including squamous cell carcinoma, hematopoietic tumors of the lymphoid system including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma, acute and chronic myeloid leukemia. For use in methods of treating certain types of cancer such as hematopoietic malignancies, myeloid hematopoietic malignancies including myelodysplastic syndromes and promyelocytic leukemia, tumors of mesenchymal origin including fibrosarcoma and rhabdomyosarcoma, tumors of the central and peripheral nervous system including astrocytoma, neuroblastoma, glioma and schwannoma, and other tumors including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, follicular thyroid carcinoma, Kaposi's sarcoma and mesothelioma.
[0124] Furthermore, the derivatives of formula (Ia) as defined above are for use in a method for the treatment of certain cell proliferation disorders such as benign prostatic hyperplasia, familial adenomatous polyposis (FAP), neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-operative stenosis and restenosis.
[0125] Furthermore, the derivatives of formula (Ia) as defined above are for use in a method for inhibiting tumour angiogenesis and metastasis, and in a method for treating organ transplant rejection and host-versus-graft disease.
[0126] The present invention also provides a method for treating cancer, comprising administering to a mammal in need thereof an effective amount of a derivative of formula (Ia) as defined above, which mammal may for example be a human.
[0127] Furthermore, the present invention provides the use of a derivative of formula (Ia) or a pharma- ceutically acceptable salt thereof as defined above in the manufacture of a medicament for the treatment of cancer, a cell proliferative disorder and a viral infection.
[0128] Finally, the present invention provides the use of an anthracycline drug reagent (I) as defined above in the preparation of a conjugate.
[0129] The anthracycline drug reagents of formula (I) defined above can be prepared according to the general synthetic process set out below in Scheme A:
[0130] [ka]
[0131] The process therefore foresees the following steps:
[0132] Step 1) Producing a compound of formula (VII):
[0133] [ka] [In the formula, X is O or NH.] with a suitable reagent for introducing a leaving group M selected from mesylate, tosylate and halogen to obtain a compound of formula (VIII),
[0134] Step 2) The compound of formula (VIII) thus obtained:
[0135] [ka] where X and M are as defined above in Step 1. with a suitable heterocyclic or carbocyclic intermediate of formula (IX),
[0136] [ka] [In the formula, A is a heterocycle or carbocycle selected from the group consisting of (IIIa) to (IIIe), R is independently hydrogen, substituted linear or branched (C1-C6) alkyl, and n is an integer of 0 to 6.]
[0137] Step 3) Reaction with an appropriate acid to obtain a compound of formula (X):
[0138] [ka] where X and A are as defined above in Step 1 and Step 2. to obtain a compound of formula (II),
[0139] Step 4) Obtained compound (II):
[0140] [ka] where X and A are as defined above in Step 1 and Step 2. with a suitable activating compound of formula (XI):
[0141] [ka] wherein W is independently absent or a group selected from formulae (Va)-(Vc), PE is absent or a dipeptide or tripeptide moiety as defined above, and RM is an optionally reactive moiety selected from formulae (VIa)-(VIc). to obtain compound (I).
[0142] According to step 1), the reaction of the compound of formula (VII) to introduce a leaving group can be carried out by various methods and experimental conditions widely known in the art. In particular, the reaction can be carried out using methanesulfonic anhydride in an organic solvent, preferably DCM, at room temperature or below, in the presence of a suitable base, preferably DMAP, collidine or pyridine, for a time ranging from about 30 minutes to about 24 hours.
[0143] According to step 2), the reaction of the compound of formula (VIII) with the compound of formula (IX) can be accomplished in a variety of ways. The reaction can be carried out in a suitable organic solvent, preferably DCM, acetone or THF, at a temperature ranging from room temperature to 40° C., for a time ranging from about 30 minutes to about 24 hours.
[0144] According to step 3), removal of the carbamate protecting group on the compound of formula (X) can be achieved by various methods and experimental conditions widely known in the art (see, for example, Protective Groups in Organic Synthesis, Theodora W. Greeen, Peter GMWuts, 4th Edition). The following acid conditions may be used: hydrogen chloride, acetic acid, trifluoroacetic acid, trichloroacetic acid or dichloroacetic acid in a solvent such as tetrahydrofuran or dichloromethane at room temperature or below.
[0145] According to step 4), the reaction of the compound of formula (II) with the compound of formula (XI) can be accomplished by various methods and experimental conditions widely known in the art for the preparation of carbamates. The reaction can be carried out in a suitable organic solvent, preferably DMF, in the presence of a suitable base, preferably TEA or DIPEA, at a temperature ranging from room temperature to 100° C., for a time ranging from about 1 hour to about 24 hours.
[0146] Compounds of general formula (VII) in which X is an O atom are commercially available or can be prepared by known methods.
[0147] Compounds of general formula (VII) in which X is NH can be prepared as described in the literature (D. Holte et al., Bioorganic & Medicinal Chemistry Letters 30 (2020), 127640).
[0148] Compounds of general formula (IX), in which A is a heterocycle or carbocycle selected from the group consisting of (IIIa) to (IIIe), can be prepared starting from commercially available intermediates as described in the experimental section below or by procedures and experimental conditions well known in the art.
[0149] Compounds of formula (XI) are commercially available or can be prepared by known methods.
[0150] From all of the above, it will be apparent to one skilled in the art that any compound of formula (I) bearing functional groups that can be further derivatized to another functional group, thus resulting in other compounds of formula (I), by working according to methods well known in the art, is intended to be included within the scope of the present invention.
[0151] When preparing compounds of general formula (I) according to any of the above-mentioned variants of the process, any functional groups in the starting materials, reagents or intermediates thereof, which may undergo undesired side reactions, must be appropriately protected according to conventional techniques (see, for example, Green, Theodora W. and Wuts, Peter GM- Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons Inc., New York (NY), 1999). Similarly, the conversion of these latter to the free deprotected compounds can be carried out according to known procedures.
[0152] Compounds of any general formula can be further transformed into other compounds of the same general formula according to methods well known in the literature, as reported in the experimental section.
[0153] According to any variation of the process for the preparation of the compounds of general formula (I), the starting materials and any other reactants are known or are readily prepared according to known methods.
[0154] The final compounds may be isolated and purified using conventional procedures, such as chromatography and / or crystallization and salt formation.
[0155] ADCs of formula (Ia) can be prepared by several routes using organic chemistry reactions, conditions, and reagents known to those of skill in the art, including (1) reacting a nucleophilic or electrophilic group on an antibody with a bivalent linker reagent to form an antibody-linker intermediate Ab-L via a covalent bond, followed by reaction with an activated drug moiety reagent, and (2) reacting a nucleophilic or electrophilic group on a drug moiety reagent with a linker reagent to form a drug-linker reagent Ant-L via a covalent bond, followed by reaction with a nucleophilic or electrophilic group on an antibody. Conjugation methods (1) and (2) can be used with a variety of antibodies, drug moieties, and linkers to prepare antibody-drug conjugates of formula (Ia).
[0156] Nucleophilic groups on an antibody include, but are not limited to, (i) N-terminal amine groups, (ii) side chain amine groups, such as lysine, (iii) side chain thiol groups, such as cysteine, and (iv) sugar hydroxyl or amino groups on which the antibody is glycosylated. Amine, thiol, and hydroxyl groups are nucleophilic and can react with electrophilic groups on linker moieties and linker reagents to form covalent bonds, including (i) active esters, such as NHS esters, HOBt esters, haloformates, and acid halides, (ii) alkyl halides and benzyl halides, such as haloacetamides, and (iii) aldehydes, ketones, carboxyls, and maleimide groups. Certain antibodies have reducible interchain disulfides, i.e., cysteine bridges. Antibodies can be made reactive for conjugation with linker reagents by treatment with reducing agents such as DTT (Cleland's Reagent, dithiothreitol) or TCEP (tris(2-carboxyethyl)phosphine hydrochloride, Getz et al. (1999) Anal. Biochem. Vol 273:73-80, Soltec Ventures, Beverly, Mass.). Thus, each cysteine disulfide bridge theoretically forms two reactive thiol nucleophiles. Additional nucleophilic groups can be introduced into antibodies by reaction of lysines with 2-iminothiolane (Traut's Reagent), resulting in conversion of amines to thiols.
[0157] Antibody-drug conjugates can also be produced by modification of the antibody to introduce electrophilic moieties that can react with nucleophilic substituents on the linker reagent or drug. The sugars of glycosylated antibodies can be oxidized, for example, with periodate oxidation reagents to form formaldehyde or ketone groups that can react with amine groups on the linker reagent or drug moiety. The resulting imine Schiff base groups can form stable bonds or can be reduced, for example, with borohydride reagents to form stable amine bonds. In one embodiment, reaction of the carbohydrate moiety of a glycosylated antibody with either galactose oxidase or sodium metaperiodate can result in carbonyl (aldehyde and ketone) groups in the protein that can react with appropriate groups on the drug (Hermanson, G. (1996) Bioconjugate Techniques, Academic Press, New York, p234-242). In another embodiment, proteins containing an N-terminal serine or threonine residue can be reacted with sodium metaperiodate resulting in the production of an aldehyde in place of the first amino acid (Geoghegan & Stroh, (1992) Bioconjugate Chem. 3:138-146, US5362852). Such aldehydes can be reacted with drug moieties or linker nucleophiles.
[0158] Similarly, nucleophilic groups on the drug moiety include, but are not limited to, (i) active esters, such as NHS esters, HOBt esters, haloformates and acid halides, (ii) alkyl halides and benzyl halides, such as haloacetamides, (iii) amines, thiols, hydroxyls, hydrazides, oximes, hydrazines, thiosemicarbazones, hydrazine carboxylates and arylhydrazides that can react with electrophilic groups on linker moieties and linker reagents, including aldehydes, ketones, carboxyls and maleimide groups, to form covalent bonds. Reactive nucleophilic groups can be introduced into anthracycline derivative compounds by standard functional group interconversions. For example, a hydroxyl group can be converted to a thiol group by Mitsunobu-type reaction to form a thiol-modified drug compound.
[0159] The antibody drug conjugate of formula (Ia) as defined above can be prepared according to the general synthetic process described later in the experimental section.
[0160] The compounds of general formula (Ia) defined above can be converted into pharmaceutically acceptable salts.The pharmaceutically acceptable salts of the compounds of formula (Ia) also include salts with inorganic or organic bases, such as alkali metals or alkaline earth metals, in particular sodium, potassium, calcium, ammonium or magnesium hydroxides, carbonates or bicarbonates, acyclic or cyclic amines.
[0161] Pharmaceutically acceptable salts of the compounds of formula (Ia) include salts with inorganic or organic acids, such as nitric acid, hydrochloric acid, hydrobromic acid, sulfuric acid, perchloric acid, phosphoric acid, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, fumaric acid, lactic acid, oxalic acid, malonic acid, malic acid, maleic acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, isothioic acid and salicylic acid.
[0162] The compounds of formula (Ia) or a pharma- ceutically acceptable salt thereof as defined above may then be formulated with a pharma- ceutically acceptable carrier or diluent to provide a pharmaceutical composition.
[0163] The synthesis of compounds of general formula (I) according to the above synthetic processes can be carried out stepwise, with each intermediate being isolated and, if necessary, purified by standard purification techniques, such as, for example, column chromatography, before carrying out the subsequent reactions. Alternatively, two or more steps of the synthetic sequence can be carried out in a so-called "one-pot" procedure, as is known in the art, whereby only the compound resulting from two or more steps is isolated and purified.
[0164] When a stereocenter or other form of isomeric center exists in the compound of the present invention, all forms of such isomer or isomers, including enantiomers and diastereomers, are intended to be included herein. Compounds containing stereocenters may be used as racemic mixtures, enantiomerically enriched mixtures, or racemic mixtures may be separated using well-known techniques, and individual enantiomers may be used alone. Such separation procedures include standard chromatographic techniques, including chromatography using chiral stationary phases, or crystallization. General methods for the separation of compounds containing one or more asymmetric centers are reported, for example, in Jacques, Jean, Collet, Andre, Wilen, Samuel H., Enantiomers, Racemates, and Resolutions, John Wiley & Sons Inc., New York (NY), 1981.
[0165] In cases in which compounds have unsaturated carbon-carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of this invention.
[0166] In cases where compounds can exist in tautomeric forms, it is contemplated that each form, whether existing in equilibrium or existing primarily in one form, is included within the present invention. EXAMPLES
[0167] <Experimental section> The short forms and abbreviations used herein have the following meanings: g (grams) mg (milligrams) mL (milliliter) μL (microliter) mM (millimol) mmol (millimol) μM (micromolar) MHz (megahertz) h time Hz (Hertz) mm (millimeters) ppm (parts per million) cm(centimeter) min(minute) μm (microns) M (moles) nM (nanomolar) TRZ (Trastuzumab) FBS (fetal bovine serum) HRMS (high resolution mass spectrum) BSA (bovine serum albumin) DTT (dithiothreitol) NADPH (nicotinamide adenine dinucleotide phosphate) Rt (retention time) 2-HG (2-hydroxyglutaric acid) KOtBu (potassium tert-butoxide) rt (room temperature) TEA (triethylamine) DMAP (4-Dimethylaminopyridine) DCA (2,2-Dichloroacetic acid) TFA (trifluoroacetic acid) Na2SO4 (sodium sulfate) Et2O (Diethyl Ether) NaHCO3 (Sodium Bicarbonate) AcOH (acetic acid) ESI (electrospray ionization) Na2CO3 (sodium carbonate) K2CO3 (potassium carbonate) Cs2CO3 (Cesium carbonate) K3PO4 (Potassium phosphate) LiOH (lithium hydroxide) NaOH (sodium hydroxide) KOH (potassium hydroxide) p-TsOH (p-toluenesulfonic acid) EtOAc (Ethyl acetate) LiHMDS (Lithium bis(trimethylsilyl)amide) NMP (N-methyl-2-pyrrolidone) NaH (sodium hydride) DMA (N,N-dimethylacetamide) KH (Potassium hydride) DMF (N,N-dimethylformamide) DCM (Dichloromethane) DIPEA (N,N-Diisopropyl-N-ethylamine) hex (Hexane) THF (Tetrahydrofuran) DMSO (Dimethyl sulfoxide) MeOH (Methanol) ACN (Acetonitrile) EtOH (Ethanol) Bn (Benzyl) OMs (Mesylate) -OTs (Tosylate) HOBT (N-Hydroxy-benzotriazole) DCC (1,3-Dicyclohexylcarbodiimide) NMR (Nuclear magnetic resonance) MS (Mass spectrometry) m / z (Mass-to-charge ratio) LC (Liquid chromatography) MgCl2 (Magnesium chloride) TLC (Thin-layer chromatography) ADC (Antibody-drug conjugate) TCEP (Tris(2-carboxyethyl)phosphine) DAR (Drug-to-antibody ratio) PBS (Phosphate-buffered saline) SDS-PAGE (Sodium dodecyl sulfate-polyacrylamide gel electrophoresis) PLRP LC / MS (Polymer reversed-phase liquid chromatography / mass spectrometry) HPLC-MS (High-performance liquid chromatography-mass spectrometry) EDCI (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) TBTU (N,N,N’,N’-Tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate) RP-HPLC (Reversed-phase high-performance liquid chromatography)
[0168] <Pharmacology> The preparation and cytotoxicity evaluation of the ADC of formula (Ia) are evaluated as follows.
[0169] <ADC Preparation (General Procedure)> The ADC was prepared by conjugating the antibody trastuzumab TRZ with the compound of formula (I) via partial reduction of the interchain disulfide bridges and subsequent derivatization of the free cysteine residues.
[0170] In particular, TRZ is treated with a range of 1.9 to 2.3 molar equivalents of the reducing agent tris(2-carboxyethyl)phosphine (TCEP) at temperatures ranging from 0 to 20° C. for 2 to 20 hours in a polar organic solvent, preferably DMA, CH3CN and / or DMSO.
[0171] Excess compound (I) was quenched with 1 mM final cysteine, and the resulting conjugate (Ia) was purified using a desalting column.
[0172] All ADCs of formula (Ia) were characterized by SDS-PAGE analysis under reducing and non-reducing conditions, size exclusion chromatography (SEC), PLRP LC / MS and hydrophobic interaction chromatography (HIC).
[0173] The average DAR was calculated by UV absorbance at different wavelengths obtained by PLRP LC analysis.
[0174] <Proliferation assay> Cells were seeded in 96-well plates at a final density of 2000-4000 cells / well in the appropriate medium + 10% FBS. After 24-48 h, cells were treated with serial compound (Ia) dilutions in duplicate. Cell viability was measured after 144 h using the Cell Titer Glo assay (Promega). IC50s were calculated using sigmoidal fitting software (Assay Explorer MDL). Experiments were repeated at least twice (n ≥ 2).
[0175] In particular, the cytotoxicity of the following ADCs was evaluated (Table 1).
[0176] <In vivo efficacy experiment> The therapeutic efficacy of the ADC compounds was evaluated in animal models of human transplanted tumors.
[0177] Athymic CD-1 nu / nu female mice (5 or 7 weeks old) were purchased from Charles River Laboratories (Calco, Italy) and maintained at 22-24 °C under pathogen-restrictive conditions as required. Cages, bedding, and food were autoclaved before use. Mice were fed standard chow and water ad libitum and allowed to acclimate for 2 weeks before the start of the experiments. Housing and all procedures involving mice were performed in accordance with a protocol approved by the Animal Experimentation Committee of the Italian Ministry of Health (authorization number 292 / 2017-PR).
[0178] Xenografts were generated by subcutaneous injection of 106 HCC1954 HER2+ human breast cancer cells (ATCC) in 200 μl of PBS into the right flank of mice. When the xenografts were palpable (approximately 150 mm 3 ), and animals were divided into groups (8 mice / group) to provide a similar range of tumor sizes for each group. Eight days after cell inoculation, treatment groups received an intravenous injection of trastuzumab or ADC in PBS at the indicated doses (single dose), while the control group (vehicle) received PBS only. Tumor volumes were monitored weekly by caliper and calculated according to the following formula: tumor volume (mm 3 )=(length x width 2 ) / 2. Mice were considered tumor-free when the tumor was no longer palpable. Animals were weighed during the observation period and toxicity was assessed based on weight loss.
[0179] Table 1 below shows the cytotoxic activity (IC50 nM) of the ADC compound of formula (Ia) in HCC1954 and NCI-N87 cell lines, while FIG. 1 and Table 2 show the cytotoxic activity (IC50 nM) of the ADC compound of the present invention (Ia iv ) against HCC1954 xenograft model.
[0180] [Table 1]
[0181] [Table 2]
[0182] ADC(Ia IV ) were tested in a xenograft model of HCC1954 (human breast cancer cell line, ErbB2+) inoculated subcutaneously in athymic nude mice. Both ADCs were administered intravenously (single treatment) 8 days after tumor injection and randomization (8 mice / group, mean tumor volume: 0.18 cm). 3 ). ADC(Ia IV ) was administered at 1 mg / Kg, 5 mg / Kg or 10 mg / Kg and showed dose-dependent tumor growth inhibition without obvious toxic effects at any dose. At the end of the experiment (113 days), 0 / 8 animals were tumor-free at 1 mg / Kg, whereas 5 / 8 and 8 / 8 mice were found to be tumor-free at 5 mg / Kg and 10 mg / Kg, respectively.
[0183] These data indicate that ADC (Ia IV ) had a remarkable therapeutic index, demonstrated tumor eradication in 8 out of 8 animals and was well tolerated at 10 mg / kg, thus indicating that the ADC of the invention is suitable for use in the treatment of cancer.
[0184] <Preparation of Compound of Formula (I)> For any particular compound of formula (I) of the present invention, optionally in the form of a pharma-ceutically acceptable salt, please refer to the experimental section and claims.With reference to the following examples, the compounds of the present invention are synthesized using the methods described herein or other methods known in the art.With the aim of better illustrating the present invention, the following examples are given without limiting the present invention in any way.As used herein, the symbols and conventions used in the processes, schemes and examples are consistent with those used in modern scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry.
[0185] The compound name is the IUPAC name created using Biovia Draw 2020 (manufactured by Dassault Systems).
[0186] Unless otherwise specified, all materials including anhydrous solvents such as DMF, THF, and DCM were obtained from commercial suppliers of the best grade and used without further purification. All reactions involving air- or moisture-sensitive compounds were carried out under a nitrogen or argon atmosphere.
[0187] <General purification and analysis methods> Flash chromatography was performed on silica gel (Merck grade 9395, 60A).
[0188] <HPLC LCQ method> HPLC-MS / UV analysis was performed using an LCQ DecaXP (Thermo, San Jose, USA) ion trap device equipped with an electrospray (ESI) ion source. The mass spectrometer was connected to a Surveyor HPLC system (Thermo, San Jose, USA) equipped with a UV photodiode array detector (UV detection 215 - 400 nm). A Waters XSelect CSH C18 column 50×4.6 mm, particle size 3.5 μm was used. Mobile phase A was 5 mM ammonium acetate buffer (pH 4.5 containing acetic acid): acetonitrile 95:5, and mobile phase B was 5 mM ammonium acetate buffer (pH 4.5 containing acetic acid): acetonitrile 5:95. A gradient from 0 to 100% B in 7 minutes, with 100% B held for 2 minutes. Flow rate 1 mL / min. Injection volume 10 μL. Retention time (HPLC r.t.) is shown in minutes. Full scan, mass range is 50 - 1200 amu. The heated capillary temperature was 200 °C, and the spray voltage value was set at 4 kV. Mass is shown as the m / z ratio.
[0189] Instrument control, data acquisition, and processing were performed using Xcalibur 1.4 SR1 software (Thermo).
[0190] <HPLC LCT method> HPLC-MS / UV analysis and high-resolution mass spectra (HRMS) were performed on a Waters Alliance LC 2795 equipped with a TOF Waters LCT Premier XE mass detector (ESI interface) supported by a Waters PDA UV detector 2996 and a Waters Reagent Manager liquid pump. The assay is based on universal gradient reversed-phase chromatography that allows the identity-purity assay to be complemented with the determination and confirmation of the expected exact mass of the compounds in the same run. Compound identification is achieved by online sequential ESI (+) full-scan MS detection and sample purity is obtained as the relative "area percent" of the integrated LC / UV trace from 216 to 400 nm. The liquid chromatograph is equipped with a Waters XBridge CSH C18 column (3.0 x 30 mm, 3.5 μm particle size) thermostatted at 50 °C. Alternatively, the Supelco column Ascentis Express C18 (2.7 x 30 mm x 3 um) was used.
[0191] Mobile phase A was 0.05% w / v formic acid in highly purified water and mobile phase B was a 70 / 25 / 5 (v / v / v) mixture of MeOH / iPrOH / H2O containing 0.035% w / v formic acid. Gradient from 0 to 100% B in 17.5 min, hold 100% B for 5 min. Flow rate 0.8 mL / min, injection volume 4 μL. The ESI source was operated at 100° C., 2.5 kV capillary voltage, 60 V cone, nitrogen desolvation flow of 600 L / h at 350° C. and nitrogen cone flow of 10 L / h. “Normal” Zfocus set to 140. The analyzer is normally optimized with a flight tube at 7200 V.
[0192] To obtain high-resolution mass spectra, the eluent from the HPLC column was split and 25 μL / min was mixed with a 100 μL / min flow of a 30 / 10 / 60 (v / v / v) mixture of MeOH / iPrOH / H2O containing 0.01% w / v formic acid and 80 nM trimethoprim coming from a Waters Reagent Manager pump before entering the MS source. Trimethoprim was selected as a stable, soluble and suitable reference compound for real-time single-point mass correction. ES(+) full scan 80-1200 amu centroid data acquisition was performed in "W" mode at a 2 Hz sampling rate. The LCT embedded PC provided both real-time data centroiding and real-time mass correction based on trimethoprim. H of 291.1452 Da was used. + MS spectra of appropriate intensity (40–2000 analyte counts) were averaged to obtain the final result.
[0193] The preparative HPLC equipment consisted of a Shimadzu HPLC system equipped with an SCL-8A System controller, two LC-8A pumps, an SPD-6A UV spectrophotometric detector and a manual Rheodyne injection system. Data acquisition (analog signal) and data processing were provided by Empower 2 software. Purification was performed on a Waters X-Terra MS RP18 (150×30 mm, 10 μm) column at 25° C. with a flow rate of 15 mL / min. Mobile phase A was 0.1% TFA in water / acetonitrile (95:5), alternatively mobile phase A was 0.05% NH3 in water / acetonitrile (95:5) and mobile phase B was H2O / acetonitrile (5:95). The gradient was 10 to 90% B in 15 min, then ramped to 100% B in 0.1 min. Injection volume maximum 500 μL.
[0194] 1 H-NMR spectra were recorded using a 5 mm NMR spectrometer operating at 400.5 MHz. 1 H{ 15 N- 31 A Varian INOVA 400 spectrometer equipped with a z-axis PFG indirect detection probe, operating at 499.7 MHz and a 5 mm 1 H{ 13C- 15 The chemical shifts were recorded at a constant temperature of 28 °C on a Varian INOVA 500 spectrometer equipped with a {N} triple resonance indirect detection probe. Chemical shifts were recorded using the non-deuterated residual solvent signal (DMSO-d5, 1 The data are reported as follows: chemical shift (δ), multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, qt=quintet, br.s=broad singlet, dd=doublet of doublets, ddd=doublet of doublet of doublets, m=multiplet), coupling constants (J, Hz) and number of protons.
[0195] The synthetic preparation of some of the compounds of formula (I) of the present invention is described in the following Examples.
[0196] Compounds of the invention prepared according to the following examples were 1 They were also characterized by H NMR and / or HPLC / MS analytical data. The HPLC / MS data were collected according to either the LCQ or LCT method.
[0197] [Example A] <Intermediate IX> [1-Methyl-1-(4-phenylphenyl)ethyl]piperazine-1-carboxylate
[0198] [ka]
[0199] To a solution of piperazine (0.517 g, 6 mmol, 3 equiv.) in DMF (2.5 mL) was added methyl 4-[1-methyl-1-(4-phenylphenyl)ethoxy]carbonyloxybenzoate (0.781 g, 2 mmol, 1 equiv.). The reaction was stirred at room temperature overnight. HPLC-MS analysis indicated the presence of the title compound. EtOAc was added to the mixture and the organic layer was washed three times with water, dried over Na2SO4, filtered and evaporated to dryness. The residue was purified by chromatography column DCM / MeOH (100 / 5-100 / 9) to give the title compound as a solid (0.600 g, 1.85 mmol, 92% yield).
[0200] 1 H NMR (500MHz, DMSO-d6) δppm 1.72 (s, 6H) 2.57~2.75 (m, 5H) 3.17 (d, J=5.34Hz, 2H) 3.37-3.51 (m, 2H) 7.34 -7.37(m, 1H)7.40(d, J=8.39Hz, 2H)7.46(t, J=7.70Hz, 2H)7.60-7.68(m, 4H)
[0201] C 20 H 24 N2O2[M+H] + HRMS (ESI) calculated value: 347.1730, measured value: 347.1735
[0202] By proceeding in a similar manner, but using appropriately substituted starting materials, the following compounds were obtained: [1-Methyl-1-(4-phenylphenyl)ethyl]4-(methylamino)piperidine-1-carboxylate
[0203] [ka]
[0204] 1H NMR (500MHz, DMSO-d6) δppm 0.99-1.27(m, 2H)1.72(s, 6H)1.75-1.90(m, 2H)2.24(br.s., 1H)2.29(s, 3H)2.69-3.09(m, 2H)3.10-3.50(m, 1H)3.75(br.s. , 1H)3.98(br.s., 1H)7.30-7.38(m, 1H)7.40(d, J=8.54Hz, 2H)7.46(t, J=7.70Hz, 2H)7.62(d, J=8.54Hz, 2H)7.64-7.68(m, 2H)
[0205] C 22 H 28 N2O2[M+H] + HRMS(ESI) calculated value: 353.2224, measured value: 353.2219
[0206] [1-Methyl-1-(4-phenylphenyl)ethyl]N-methyl-N-(4-piperidyl)carbamate
[0207] [ka]
[0208] 1 H NMR (600MHz, DMSO-d6) δppm 1.34-1.65(m, 4H)1.73(s, 6H)2.41(m, 1H)2.59-3.09(m, 6H)3.72-3.96(m, 2H)7.33-7.37(m, 1H)7.38-7.42(m, 2H)7.43-7.48(m, 2H)7.61(d, J=8.36Hz, 2H)7.65(dd, J=8.27, 1.00Hz, 2H)
[0209] C 22 H 28 N2O2[M+H] + HRMS (ESI) calculated value: 353.2224, found value: 353.2227
[0210] [1-methyl-1-(4-phenylphenyl)ethyl]1,4-diazepane-1-carboxylate
[0211] [ka]
[0212] 1 H NMR (600MHz, DMSO-d6) δppm 1.58(t, J=5.63Hz, 1H)1.73(s, 6H)1.74-1.79(m, 1H)2.65-2.71(m, 2H) 2.75(t, J=5.81Hz, 1H)2.81-2.87(m, 1H)3.20-3.25(m, 1H)3.29-3.40( m, 2H)3.44-3.48(m, 1H)3.52(t, J=6.09Hz, 1H)7.32-7.38(m, 1H)7.39-7.44(m, 2H)7.44-7.48(m, 2H)7.61(d, J=7.99Hz, 2H)7.63-8.51(m, 2H)
[0213] C 21 H 26 N2O2[M+H] + HRMS(ESI) calculated value: 339.2067, measured value: 339.2071
[0214] <Step 1> [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]methanesulfonate (VIII)
[0215] [ka]
[0216] (8S,10S)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-12-imino-1-methoxy-10-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-9 in dry DCM (5 mL), To a solution of 10-dihydro-7H-tetracen-5-one (0.025 g, 0.039 mmol, 1 equiv.), 2,4,6-collidine (0.019 g, 0.156 mmol, 4 equiv.) and 4-(dimethylamino)pyridine (0.005 g, 0.039 mmol, 1 equiv.) was added methanesulfonic anhydride (0.027 g, 0.156 mmol, 4 equiv.). The reaction was stirred at room temperature for 5 h. HPLC-MS analysis indicated the presence of the title compound. Water and DCM were added to the mixture and the organic layer was washed three times with water, dried over Na2SO4, filtered and evaporated to dryness. The crude was triturated with Et2O and filtered three times to give the title compound as a blue solid (0.028 g, 0.039 mmol, 100% yield).
[0217] C 33 H 38 N2O 14 S[M+H] + HRMS (ESI) calculated value: 719.2117, measured value: 719.2122
[0218] By proceeding in a similar manner, but using appropriately substituted starting materials, the following compounds were obtained:
[0219] [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]methanesulfonate (VIII)
[0220] [ka]
[0221] Red solid (0.0035 g, 0.0049 mmol, 74% yield).
[0222] 1 H NMR (500MHz, DMSO-d6) δppm 1.24(d, J=6.10Hz, 3H)1.64-1.72(m, 2H)2.13-2.19(m, 1H)2.27(d, J=15.50Hz, 1H)2.60-2.73(m, 2H)2.90 -3.11 (m, 2H) 3.26 (s, 3H) 3.31 (s, 3H) 3.35-3.41 (m, 1H) 3.47-3.53 (m, 1H) 3.62-3.71 (m, 1H) 3.94 (d, J=6.35 Hz, 1H)4.00(s, 3H)4.12-4.20(m, 1H)4.21-4.25(m, 1H)4.59(s, 1H)5.02(br.s., 1H)5.24(t, J=4.27Hz, 1H) 5.37-5.50(m, 2H)5.58(s, 1H)7.59-7.72(m, 1H)7.93(d, J=4.27Hz, 2H)13.28(br.s., 1H)14.07(br.s., 1H)
[0223] C 33 H 37 NO 15 S[M+H] + HRMS(ESI) calculated value: 720.1957, found value: 720.1969
[0224] <Step 2> [1-methyl-1-(4-phenylphenyl)ethyl]4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate (X) (X=NH, A=(IIIb') (wherein R is a methyl group))
[0225] [ka]
[0226] [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]methanesulfonate (0.028 g, 0.039 mmol, 1 equiv.) and [1-methyl-1-(4-phenylphenyl)ethyl]4-(methylamino)piperidine-1-carboxylate (0.083 g, 0.234 mmol, 6 equiv.) were dissolved in dry DCM (10 mL). The solvent was removed under reduced pressure (rotary evaporator) and redissolved in dry DCM (3 mL). The solvent was removed under reduced pressure (rotary evaporator) and the sequence of solubilization and evaporation was repeated until the starting material ([2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]methanesulfonate) was no longer detectable by HPLC-MS and / or TLC. The crude was purified by chromatography column DCM / acetone (8 / 2 to 7 / 3) to give the title compound as a blue solid (0.015 g, 0.0154 mmol, 39% yield).
[0227] 1H NMR (600MHz, DMSO-d6) δppm 1.19-1.27(m, 5H)1.60-1.64(m, 2H)1.72(m, 8H)2.05-2.11(m, 1H)2.12-2.17(m, 1H) )2.23(s, 3H)2.56-2.60(m, 1H)2.63-2.68(m, 2H)2.56-2.98(br.s, 2H)2.83-2.88( m, 1H) 2.93-2.98 (m, 1H) 3.29 (s, 3H) 3.34 (m, 1H) 3.45-3.51 (m, 1H) 3.60-3.94 (br.S ., 2H)3.62-3.68(m, 1H)3.73-3.83(m, 2H)3.91-3.93(m, 1H)4.12(s, 3H)4.16(m, J= 6.63Hz, 1H)4.23(d, J=2.00Hz, 1H)4.58(d, J=1.91Hz, 1H)5.03(t, J=4.29Hz, 1H)5. 37(s, 1H) 5.40(t, J=4.59Hz, 1H) 7.31-7.36(m, 1H) 7.38-7.42(m, 2H) 7.44(t, J=7.7 4Hz, 2H)7.62(d, J=8.49Hz, 2H)7.63-7.67(m, 3H)7.87(t, J=8.08Hz, 1H)8.08(dd, J =7.83,0.98Hz, 1H)9.67(d, J=4.68Hz, 1H)13.60(d, J=5.04Hz, 1H)15.89(br.s., 1H)
[0228] C 54 H 62 N4O 13 [M+H] + HRMS (ESI) calculated value 975.4386, observed value 975.4381
[0229] By proceeding in a similar manner, but using appropriately substituted starting materials (Intermediates VIII and IX), the following compounds were obtained:
[0230] [1-Methyl-1-(4-phenylphenyl)ethyl]4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate (X) (X=NH, A=(IIIa'))
[0231] [ka]
[0232] Blue solid (0.016 g, 0.017 mmol, 60% yield).
[0233] 1 H NMR (500MHz, DMSO-d6) δppm 1.21-1.28(m, 3H)1.59-1.66(m, 2H)1.72(s, 6H)2.05-2.18(m, 2H)2.36-2.49(m, 4H)2.58-2.71(m, 2H)2.82-2.97(m, 2H)3.18-3.38(m, 5 H)3.31(s, 3H)3.47-3.55(m, 2H)3.62-3.75(m, 3H)3.94(d, J=7.52Hz, 1H)4.12(s, 3H)4.14-4.18(m, 1H)4.24(d, J=1.82Hz, 1H)4.60(d, J= 1.69Hz, 1H)5.01-5.09(m, 1H)5.38(s, 1H)5.41(t, J=4.41Hz, 1H)7.33-7.38(m, 1H)7.40(d, J=8.43Hz, 2H)7.47(t, J=7.65Hz, 2H)7.62(d , J=8.30Hz, 2H)7.66(d, J=7.65Hz, 2H)7.86(t, J=7.65Hz, 1H)8.09(d, J=7.78Hz, 1H)9.67(br.s., 1H)13.59(br.s., 1H)15.90(br.s., 1H)
[0234] C 52 H 58 N4O13 [M+H] + HRMS (ESI) calculated value: 947.4073, found value: 947.4069
[0235] [1-methyl-1-(4-phenylphenyl)ethyl]N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate (X) (X=NH, A=(IIIc') (wherein R is a methyl group))
[0236] [ka]
[0237] Blue solid (0.008 g, 0.0082 mmol, 49% yield).
[0238] 1 H NMR (600MHz, DMSO-d6) δppm 1.15-1.42(m, 7H)1.62-(m, 2H)1.72(s, 6H)1.95-2.19(m, 4H)2.52-3.00(m, 9H)3.30(s, 3H)3.34-3.39(m, 1H)3 .37(m, 1H)3.47-3.75(m, 4H)3.66(t, J=9.20Hz, 1H)3.91-3.95(m, 1H)4.07-4.18(m, 4H)4.23(d, J=1.54Hz, 1H) 4.59(d, J=1.91Hz, 1H)5.05(br.s., 1H)5.40(br.s., 2H)7.31-7.43(m, 3H)7.46(t, J=7.74Hz, 2H)7.54-7.68(m , 5H)7.87(t, J=8.08Hz, 1H)8.04-8.11(m, 1H)9.65(d, J=4.59Hz, 1H)13.56(d, J=4.54Hz, 1H)15.91(br.s., 1H)
[0239] C 54 H 62 N4O 13 [M+H] + HRMS (ESI) calculated value 975.4386, observed value 975.4390
[0240] [1-methyl-1-(4-phenylphenyl)ethyl]4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate (X) (X=O, A=(IIIb') (wherein R is a methyl group))
[0241] [ka]
[0242] Red solid (0.0065 g, 0.0067 mmol, 51% yield)
[0243] C 54 H 61 N3O 14 [M+H] + HRMS (ESI) calculated value 976.4226, found value 976.4229
[0244] [1-Methyl-1-(4-phenylphenyl)ethyl]4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate (X) (X=O, A=(IIIa'))
[0245] [ka]
[0246] Red solid (0.052 g, 0.054 mmol, 70% yield).
[0247] C 52 H 57 N3O 14 [M+H] + HRMS (ESI) calculated value: 948.3914, observed value: 948.3904
[0248] [1-methyl-1-(4-phenylphenyl)ethyl]N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate (X) (X=O, A=(IIIc') (wherein R is a methyl group))
[0249] [ka]
[0250] Red solid (0.0033 g, 0.0034 mmol, 61% yield)
[0251] 1H NMR (600MHz, DMSO-d6) δppm 1.25(m, 3H)1.71-1.76(m, 6H)1.37-1.69(m, 6H)1.96-2.23(m, 4H)2.62-3.10(m, 8H)3.30(br.s, 3H)3.35-3.40(m, 1H)3 .47-3.53(m, 1H)3.47-3.74(m, 4H)3.66(m, 1H)3.93(d, J=5.45Hz, 1H)3.99(s, 3H)4.17(d, J=7.13Hz, 1H)4.23(d, J=1.77 Hz, 1H)4.59(d, J=1.95Hz, 1H)5.00(br.s., 1H)5.23(br.s., 1H)5.47(br.s., 1H)7.31-7.38(m, 1H)7.39(d, J=8.36Hz, 2 H)7.46(t, J=7.74Hz, 2H)7.61(d, J=8.36Hz, 2H)7.63-7.73(m, 3H)7.88-7.96(m, 2H)13.28(br.s., 1H)14.06(br.s., 1H)
[0252] C 54 H 61 N3O 14 [M+H] + HRMS (ESI) calculated value: 976.4226, found value: 976.4221
[0253] [1-methyl-1-(4-phenylphenyl)ethyl]4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-1,4-diazepane-1-carboxylate (X) (X=O, A=(IIIa”))
[0254] [ka]
[0255] Red solid (0.0045 g, 0.0047 mmol, 64% yield)
[0256] 1 H NMR (600MHz, DMSO-d6)λppm 1.19-1.28(m, 3H)1.66(m, 3H)1.69-1.75(m, 6H)1.81(m, 1H)2.04-2.26(m, 2H)2.57-2.70(m, 5H)2.79(t, J=5.00 Hz, 1H)2.90-3.09(m, 2H)3.30(s, 3H)3.26-3.34(m, 2H)3.36(m, 1H)3.44-3.56(m, 3H)3.66(m, 1H)3.84-3.94(m, 3H)3.99(s, 3H)4.18(m, 1H)4.23(d, J=1.82Hz, 1H)4.58(d, J=2.00Hz, 1H)4.93-5.06(m, 1H)5.23(m, 1H)5.35-5. 51(m, 1H)7.29-7.37(m, 1H)7.38-7.49(m, 4H)7.54-7.71(m, 5H)7.89-7.95(m, 2H)13.27(br.s., 1H)14.03(s, 1H)
[0257] C 53 H 59 N3O 14 [M+H] + HRMS (ESI) calculated value: 962.4070, found value: 962.4073
[0258] <Step 3> (8S,10S)-6,8,11-trihydroxy-12-imino-1-methoxy-10-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-8-[2-[methyl(4-piperidyl)amino]acetyl]-9,10-dihydro-7H-tetracen-5-one (II) (compound 17, X=NH, A=(IIIb') (wherein R is a methyl group))
[0259] [ka]
[0260] To a solution of [1-methyl-1-(4-phenylphenyl)ethyl] 4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate (0.0145 g, 0.0149 mmol, 1 equiv.) in dry DCM (4 mL) at T=0° C. was added 2,2-dichloroacetic acid (2.0 mL, 0.297 mmol, 20 equiv.). The reaction was kept at T=0° C. for 15 min and then stirred at room temperature for 4 h. TLC analysis showed complete conversion of starting material to the title product. The reaction mixture was poured into a separatory funnel with a saturated aqueous solution of NaHCO3. The aqueous layer was washed three times with DCM and the combined organic phases were dried over Na2SO4, filtered and evaporated to dryness. The crude was purified by chromatography column DCM / MeOH (95 / 5 to 9 / 1) to give the title compound as a blue solid (0.008 g, 0.01 mmol, 68% yield).
[0261] 1H NMR (600MHz, DMSO-d6) δppm 1.23 (m, 3H) 1.45-1.65 (m, 4H) 1.80-1.86 (m, 2H) 1.92-2.0 (m, 2H) 2.86 (m, 1H) 2.07 (dd, J=14.76, 6.13, 1H) 2.14 (dd, J=14.76, 3.22, 1H) 2.22 (s, 3H)2.59-2.69(m, 2H)2.73(m, 1)2.82(m, 2H)2.92-2.98(m, 1H)3.23-3.33(m, 2H)3.30(s, 3H)3.37(m, 1H)3.49(m, 1H)3.66(m, 1H)3.79(s , 2H)3.93(dd, J=6.34, 1.70Hz, 1H)4.10-4.17(m, 4H)4.24(d, J=2.00Hz, 1H)4.59(d, J=1.95Hz, 1H)5.01-5.05(m, 1H)5.36(m, 1H)5.40(t, J= 4.61Hz, 1H)7.65(d, J=8.45Hz, 1H)7.88(t, J=8.08Hz, 1H)8.07-8.11(m, 1H)9.68(d, J=5.00Hz, 1H)13.61(d, J=5.00Hz, 1H)15.88(br.s., 1H)
[0262] C 38 H 48 N4O 11 [M+H] + HRMS(ESI) calculated value 737.3392, found value 737.3389
[0263] By proceeding in a similar manner but using the appropriately substituted starting material (Intermediate X), the following compounds were obtained:
[0264] (8S,10S)-6,8,11-trihydroxy-12-imino-1-methoxy-10-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-8-(2-piperazin-1-ylacetyl)-9,10-dihydro-7H-tetracen-5-one (II) (compound 18, X = NH, A = (IIIa'))
[0265]
Chem.
[0266] Blue solid (0.007 g, 0.0099 mmol, yield 72%).
[0267] 1 H NMR (500 MHz, DMSO-d6) δ ppm 1.24 (d, J = 6.59 Hz, 3H) 1.57 - 1.67 (m, 2H) 2.02 - 2.09 (m, 1H) 2.10 - 2.16 (m, 1H) 2.29 - 2.37 (m, 4H) 2.57 - 2.64 (m, 1H) 2.65 - 2.72 (m, 5H) 2.80 - 2.97 (m, 2H) 3.31 (s, 3H) 3.34 (m, 1H) 3.47 - 3.53 (m, 1H) 3.57 (d, J = 1.10 Hz, 2H) 3.63 - 3.70 (m, 1H) 3.93 (d, J = 7.87 Hz, 1H) 4.12 (s, 3H) 4.14 - 4.19 (m, 1H) 4.24 (d, J = 1.83 Hz, 1H) 4.60 (d, J = 1.65 Hz, 1H) 5.03 (t, J = 4.21 Hz, 1H) 5.37 (s, 1H) 5.40 (t, J = 4.49 Hz, 1H) 7.64 (d, J = 8.06 Hz, 1H) 7.87 (t, J = 8.15 Hz, 1H) 8.08 (d, J = 7.87 Hz, 1H) 9.66 (d, J = 4.76 Hz, 1H) 13.58 (d, J = 4.76 Hz, 1H) 15.65 (br.s, 1H)
[0268] C 36 H 44 N4O 11 [M + H] + Calculated HRMS (ESI) value for [M + H] 709.3080, measured value 709.3066
[0269] (8S,10S)-6,8,11-trihydroxy-12-imino-1-methoxy-10-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-8-[2-[4-(methylamino)-1-piperidyl]acetyl]-9,10-dihydro-7H-tetracen-5-one (II) (compound 19, X=NH, A=(IIIc') (wherein R is a methyl group))
[0270] [ka]
[0271] Blue solid (0.001 g, 0.0014 mmol, 19% yield)
[0272] C 38 H 48 N4O 11 [M+H] + HRMS (ESI) calculated value 737.3392, found value 737.3399
[0273] (7S,9S)-6,9,11-trihydroxy-4-methoxy-7-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-9-[2-[methyl(4-piperidyl)amino]acetyl]-8,10-dihydro-7H-tetracene-5,12-dione (II) (compound 20, X=O, A=(IIIb') (wherein R is a methyl group))
[0274] [ka]
[0275] Red solid (0.0031 g, 0.0042 mmol, 38% yield)
[0276] C 38 H 47N3O 12 [M+H] + HRMS (ESI) calculated value: 738.3233, observed value: 738.3238
[0277] (7S,9S)-6,9,11-trihydroxy-4-methoxy-7-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-9-(2-piperazin-1-ylacetyl)-8,10-dihydro-7H-tetracene-5,12-dione (II) (compound 21, X=O, A=(IIIa'))
[0278] [ka]
[0279] Red solid (0.011 g, 0.016 mmol, 86% yield)
[0280] 1 H NMR (500MHz, DMSO-d6) δppm 1.24(d, J=6.59Hz, 3H)1.63-1.72(m, 2H)2.08-2.16(m, 1H)2.17-2.23(m, 1H)2.27-2.39(m, 4H)2.5 8-2.73(m, 6H)2.87-3.04(m, 2H)3.30(s, 3H)3.38(m, 1H)3.46-3.54(m, 3H)3.58(s, 2H)3.64-3.70( m, 1H) 3.93 (d, J = 7.08Hz, 1H) 3.99 (s, 3H) 4.15-4.21 (m, 1H) 4.23 (d, J = 1.59Hz, 1H) 4.59 (d, J = 1.46H) z, 1H)4.99(t, J=4.33Hz, 1H)5.23(t, J=4.33Hz, 1H)5.47(s, 1H)7.64-7.71(m, 1H)7.89-7.95(m, 2H)
[0281] C 36 H 43 N3O 12 [M+H] +HRMS (ESI) calculated value: 710.2920, found value: 710.2923
[0282] (7S,9S)-6,9,11-trihydroxy-4-methoxy-7-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-9-[2-[4-(methylamino)-1-piperidyl]acetyl]-8,10-dihydro-7H-tetracene-5,12-dione (II) (compound 22, X=O, A=(IIIc') (wherein R is a methyl group))
[0283] [ka]
[0284] Red solid (0.007 g, 0.0095 mmol, 93% yield)
[0285] C 38 H 47 N3O 12 [M+H] + HRMS (ESI) calculated value: 738.3233, observed value: 738.3229
[0286] (7S,9S)-9-[2-(1,4-diazepan-1-yl)acetyl]-6,9,11-trihydroxy-4-methoxy-7-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-8,10-dihydro-7H-tetracene-5,12-dione (II) (compound 23, X=O, A=(IIIa”))
[0287] [ka]
[0288] Red solid (0.015 g, 0.02 mmol, 81% yield)
[0289] C 37 H 45 N3O 12 [M+H] + HRMS (ESI) calculated value: 724.3076, observed value: 724.3073
[0290] <Step 4> [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-1 0-Methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate - Compound 1 (Formula (I)), X = NH, A = (IIIb') (wherein R is a methyl group), L = (IVa) (wherein r is 5))
[0291] [ka]
[0292] (8S,10S)-6,8,11-trihydroxy-12-imino-1-methoxy-10-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-8-[2-[methyl(4-piperidyl)amino]acetyl]-9,10-dihydro-7H-tetracen-5-one (0.0038 g, 0.0051 mmol, To a solution of [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl(4-nitrophenyl)carbonate (0.0038 g, 0.0051 mmol, 1 equiv.) and TEA (0.0026 g, 0.0256 mmol, 0.0036 mL, 5 equiv.) were added. The reaction mixture was stirred at room temperature overnight. The solvent was evaporated to dryness by rotary evaporator using a high vacuum pump. The crude was purified by chromatography column DCM / MeOH (98 / 2-9 / 1) to give the title compound as a blue solid (0.0065 g, 0.0067 mmol, 38% yield).
[0293] C 67 H 86 N 10 O 19 [M+H] + HRMS(ESI) calculated value 1335.6144, found value 1335.6139
[0294] By proceeding in a similar manner, but using appropriately substituted starting materials (Intermediates XI and XII), the following compounds were obtained:
[0295] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-meth oxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate - Compound 2 (Formula (I)), X = NH, A = (IIIb') (wherein R is a methyl group), L = (IVb) (wherein r is 5))
[0296] [ka]
[0297] Blue solid (0.002 g, 0.0016 mmol, 34% yield).
[0298] 11H NMR (600 MHz, DMSO-d6) δ ppm 0.80 - 0.83 (m, 3H) 0.83 - 0.90 (m, 3H) 1.14 - 1.39 (m, 6H) 1.30 (d, J = 7.04 Hz, 3H) 1.44 - 1.72 (m, 7H) 1.95 (dd, J = 13.35, 6.58 Hz, 1H) 2.06 - 2.20 (m, 4H) 2.57 - 2.69 (m, 2H) 2.84 (d, J = 18.0 Hz, 1H) 2.94 (d, J = 18.0 Hz, 1H) 3.29 - 3.38 (m, 8H) 3.30 (s, 3H) 3.34 - 3.39 (m, 5H) 3.50 (m, 1H) 3.63 - 3.69 (m, 1H) 3.75 (m, 2H) 3.87 - 4.03 (m, 2H) 3.93 (dd, J = 6.49, 1.62 Hz, 1H) 4.15 (m, 2H) 4.12 (m, 3H) 4.24 (m, 1H) 4.34 - 4.43 (m, 1H) 4.57 - 4.63 (m, 1H) 4.91 - 5.05 (m, 3H) 5.33 (s, 1H) 5.37 - 5.43 (m, 1H) 6.94 - 7.03 (m, 2H) 7.25 - 7.32 (m, 2H) 7.58 (d, J = 8.45 Hz, 2H) 7.64 (d, J = 8.40 Hz, 1H) 7.80 (d, J = 8.67 Hz, 1H) 7.82 - 7.91 (m, 1H) 8.08 (d, J = 7.58 Hz, 1H) 8.15 (d, J = 6.95 Hz, 1H) 9.52 - 9.72 (m, 1H) 9.94 (s, 1H) 13.59 (br.s., 1H) 15.62 - 16.06 (m, 1H)
[0299] C 64 H 80 N8O 18 [M + H] + The calculated value of HRMS (ESI) for [M + H] is 1249.5663, and the measured value is 1249.5658
[0300] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R, 10S)-10-Methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate - Compound 3 (Formula (I)), X = NH, A = (IIIa'), L = (IVa) (wherein r is 5))
[0301] [ka]
[0302] Blue solid (0.0037 g, 0.0028 mmol, 40% yield).
[0303] 11H NMR (600 MHz, DMSO-d6) δ ppm 0.82 (d, J = 6.82 Hz, 3H) 0.85 (d, J = 6.82 Hz, 3H) 1.12 - 1.20 (m, 2H) 1.23 (d, = 6.38 Hz, 3H) 1.30 - 1.53 (m, 6H) 1.54 - 1.65 (m, 3H) 1.65 - 1.74 (m, 1H) 1.96 (m, 1H) 2.03 - 2.22 (m, 4H) 2.40 (br.s., 4H) 2.62 (m, 1H) 2.67 (m, 1H) 2.85 (d, J = 18.00, 1H) 2.90 (d, J = 18.00, 1H) 2.91 - 2.97 (m, 1H) 3.03 (m, 1H) 3.30 (s, 3H) 3.33 - 3.42 (m, 7H) 3.50 (m, 1H) 3.61 - 3.72 (m, 3H) 3.93 (m, 1H) 4.12 (s, 3H) 4.14 (m, 1H) 4.19 (dd, J = 8.58, 7.26, 1H) 4.23 (d, J = 1.98 Hz, 1H) 4.38 (m, 1H) 4.60 (d, J = 1.76 Hz, 1H) 4.99 (s, 2H) 5.05 (t, J = 3.52 Hz, 1H) 5.34 (s, 1H) 5.40 (s, 3H) 5.96 (t, J = 5.72 Hz, 1H) 7.00 (s, 2H) 7.28 (d, J = 8.58 Hz, 2H) 7.59 (d, J = 8.58 Hz, 2H) 7.64 (d, J = 8.36 Hz, 1H) 7.80 (d, J = 8.80 Hz, 1H) 7.87 (t, J = 7.92 Hz, 1H) 8.08 (m, 2H) 9.66 (d, J = 5.00 Hz, 1H) 9.99 (s, 1H) 13.59 (d, J = 5.00 Hz, 1H) 15.88 (s, 1H)
[0304] C 65 H 82 N 10 O 19 [M + H] + Calculated HRMS (ESI) value for [M + H] is 1307.5831, measured value is 1307.5836
[0305] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S) -10-Methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate - Compound 4 (Formula (I)), X = NH, A = (IIIa'), L = (IVb) (wherein r is 5))
[0306] [ka]
[0307] Blue solid (0.0075 g, 0.0061 mmol, 73% yield).
[0308] 11H NMR (500 MHz, DMSO-d6) δ ppm 0.82 (d, J = 6.70, 3H) 0.86 (d, J = 6.70, 3H) 1.12 - 1.26 (m, 5H) 1.30 (d, J = 7.13 Hz, 3H) 1.39 - 1.52 (m, 4H) 1.55 - 1.68 (m, 2H) 1.90 - 2.22 (m, 5H) 2.40 (br.s., 3H) 2.57 - 2.72 (m, 3H) 2.81 - 2.95 (m, 2H) 3.30 (s, 4H) 3.33 - 3.40 (m, 7H) 3.45 - 3.55 (m, 1H) 3.63 - 3.75 (m, 3H) 3.93 (d, J = 7.26 Hz, 1H) 4.12 (s, 3H) 4.14 - 4.20 (m, 1H) 4.23 (d, J = 1.56 Hz, 1H) 4.33 - 4.42 (m, 1H) 4.59 (s, 1H) 4.99 (s, 2H) 5.02 - 5.07 (m, 1H) 5.35 (br.s., 1H) 5.40 (t, J = 4.48 Hz, 1H) 7.00 (s, 2H) 7.29 (d, J = 8.43 Hz, 2H) 7.58 (d, J = 8.43 Hz, 2H) 7.64 (d, J = 6.36 Hz, 1H) 7.82 (d, J = 8.56 Hz, 1H) 7.86 (m, 1H) 8.08 (d, J = 7.91 Hz, 1H) 8.18 (d, J = 6.88 Hz, 1H) 9.67 (br.s., 1H) 9.96 (s, 1H) 13.59 (br.s., 1H) 15.88 (br.s., 1H)
[0309] C 62 H 76 N8O 18 [M + H] + Calculated HRMS (ESI) value for [M + H] 1221.5351, measured value 1221.5363
[0310] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10 S)-10-Methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate - Compound 5 (Formula (I)), X = NH, A = (IIIc') (wherein R is a methyl group), L = (IVa) (wherein r is 5))
[0311] [ka]
[0312] Blue solid (0.0065 g, 0.0049 mmol, 41% yield).
[0313] C 67 H 86 N 10 O 19 [M+H] + HRMS(ESI) calculated value 1335.6144, found value 1335.6151
[0314] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-1 0-Methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate - Compound 6 (Formula (I)), X = NH, A = (IIIc') (wherein R is a methyl group), L = (IVb) (wherein r is 5))
[0315] [ka]
[0316] Blue solid (0.012 g, 0.0096 mmol, 28% yield).
[0317] C 64 H 80 N8O 18 [M+H] + HRMS (ESI) calculated value 1249.5663, observed value 1249.5670
[0318] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-meth oxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate - Compound 7 (Formula (I)), X=O, A=(IIIb') (wherein R is a methyl group), L=(IVa) (wherein r is 5))
[0319] [ka]
[0320] Red solid (0.0027 g, 0.002 mmol, 43% yield).
[0321] C 67 H 85 N9O 20 [M+H] + HRMS(ESI) calculated value 1336.5984, found value 1336.5991
[0322] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6 -Methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate - Compound 8 (Formula (I)), X=O, A=(IIIb') (wherein R is a methyl group), L=(IVb) (wherein r is 5))
[0323] [ka]
[0324] Red solid (0.0048 g, 0.0038 mmol, 46% yield).
[0325] C 64 H 79 N7O 19 [M+H] + HRMS (ESI) calculated value 1250.5504, observed value 1250.5510
[0326] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S) -10-Methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate - Compound 9 (Formula (I)), X=O, A=(IIIa'), L=(IVa) (wherein r is 5))
[0327] [ka]
[0328] Red solid (0.0044 g, 0.0034 mmol, 64% yield).
[0329] C 65 H 81 N9O 20 [M+H] + HRMS(ESI) calculated value 1308.5671, found value 1308.5679
[0330] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10- Methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate - Compound 10 (Formula (I)), X=O, A=(IIIa'), L=(IVb) (wherein r is 5))
[0331]
Chem.
[0332] Red solid (0.0085 g, 0.007 mmol, 62% yield).
[0333] 1 H NMR (500 MHz, DMSO-d6) δ ppm 0.78 - 0.88 (m, 6H) 1.13 - 1.20 (m, 2H) 1.23 (m, 3H) 1.30 (d, J = 7.08 Hz, 3H) 1.41 - 1.53 (m, 4H) 1.66 (br.s., 2H) 1.91 - 2.03 (m, 1H) 2.07 - 2.23 (m, 4H) 2.39 (br.s., 4H) 2.57 - 2.72 (m, 2H) 2.95 (q, J = 17.90 Hz, 2H) 3.30 (s, 3H) 3.31 - 3.40 (m, 7H) 3.46 - 3.54 (m, 1H) 3.60 - 3.73 (m, 3H) 3.93 (d, J = 7.45 Hz, 1H) 3.99 (s, 3H) 4.14 - 4.20 (m, 2H) 4.23 (d, J = 1.83 Hz, 1H) 4.38 (t, J = 7.08 Hz, 1H) 4.59 (d, J = 1.71 Hz, 1H) 4.99 (s, 3H) 5.22 (t, J = 4.21 Hz, 1H) 5.45 (s, 1H) 7.00 (s, 2H) 7.29 (d, J = 8.55 Hz, 2H) 7.58 (d, J = 8.42 Hz, 2H) 7.66 (d, J = 6.23 Hz, 1H) 7.81 (d, J = 8.67 Hz, 1H) 7.89 - 7.96 (m, 2H) 8.17 (d, J = 6.84 Hz, 1H) 9.95 (s, 1H) 13.13 - 13.42 (m, 1H) 13.89 - 14.18 (m, 1H)
[0334] C 62 H 75 N7O 19 [M + H] + Calculated HRMS (ESI) value for [M + H] 1222.5191, measured value 1222.5194
[0335] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-1 0-Methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate - Compound 11 (Formula (I)), X=O, A=(IIIc') (wherein R is a methyl group), L=(IVa) (wherein r is 5))
[0336] [ka]
[0337] Red solid (0.0075 g, 0.0056 mmol, 44% yield).
[0338] C 67 H 85 N9O 20 [M+H] + HRMS(ESI) calculated value 1336.5984, found value 1336.5979
[0339] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-meth oxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate - Compound 12 (Formula (I)), X=O, A=(IIIc') (wherein R is a methyl group), L=(IVb) (wherein r is 5))
[0340] [ka]
[0341] Red solid (0.0043 g, 0.0034 mmol, 28% yield).
[0342] 11H NMR (600 MHz, DMSO-d6) δ ppm 0.77 - 0.91 (m, 6H) 0.80 (m, 2H) 1.23 (d, J = 6.54, 3H) 1.30 (d, J = 7.27 Hz, 3H) 1.40 - 1.52 (m, 6H) 1.64 - 1.69 (m, 4H) 1.95 (m, 1H) 2.02 - 2.24 (m, 6H) 2.69 - 2.68 (m, 2H) 2.70 (s, 3H) 2.83 (m, 2H) 2.90 (d, J = 17.98 Hz, 1H) 3.02 (d, J = 17.98 Hz, 1H) 3.30 (s, 3H) 3.34 - 3.39 (m, 3H) 3.50 (m, 1H) 3.55 - 3.64 (m, 2H) 3.66 (m, 1H) 3.93 (m, 1H) 3.99 (s, 3H) 4.16 (dd, J = 8.63, 6.99 Hz, 2H) 4.23 (d, J = 2.00 Hz, 1H) 4.38 (m, 2H) 4.59 (d, J = 2.00 Hz, 1H) 4.90 - 5.04 (m, 3H) 5.23 (t, J = 4.54 Hz, 1H) 5.47 (s, 1H) 6.99 (s, 2H) 7.22 - 7.34 (m, 2H) 7.54 - 7.61 (m, 2H) 7.67 (m, 1H) 7.80 (d, J = 8.72 Hz, 1H) 7.87 - 95 (m, 2H) 8.15 (d, J = 7.08 Hz, 1H) 9.93 (s, 1H) 13.28 (br.s., 1H) 14.05 (br.s., 1H)
[0343] C 64 H 79 N7O 19 [M + H] + HRMS (ESI) calcd for [M + H]+ 1250.5504, found 1250.5507
[0344] [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-meth 1-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-1,4-diazepane-1-carboxylate - Compound 16 (Formula (I)), X=O, A=(IIIa"), L=(IVb) (wherein r is 5))
[0345] [ka]
[0346] Red solid (0.0081 g, 0.0065 mmol, 61% yield).
[0347] C 63 H 77 N7O 19 [M+H] + HRMS (ESI) calculated value 1236.5347, observed value 1236.5351
Claims
1. Anthracycline-linker reagents of formula (I): [Formula 1] [In the formula, Ant is an anthracycline drug moiety of formula (II), [Case 2] During the ceremony, X is O or NH; A is a heterocycle (Het) or a carbocycle (Cb) selected from the group consisting of (IIIa) to (IIIe); [C3] During the ceremony, R is independently hydrogen or a straight or branched chain (C 1 ~C 6 ) alkyl; n is an integer from 0 to 6, L is a linker of formula (VI), [C4] During the ceremony, W is independently absent or a self-immolative system selected from the group consisting of (Va)-(Vc); [C5] During the ceremony, R1 and R2 are each independently hydrogen, halogen, methyl, ethyl, or linear or branched C 1 ~C 4 is hydroxyalkyl, PE is independently an absent or dipeptide or tripeptide moiety consisting of any combination of naturally occurring L-amino acids and non-naturally occurring D-amino acids; RM is a reactive moiety selected from the group consisting of (VIa)-(VIc); [C6] During the ceremony, R3 and R4 are each independently hydrogen, halogen, methyl, ethyl, straight or branched C 1 ~C 4 Hydroxyalkyl, linear or branched C 1 ~C 4 haloalkyl, or R3 and R4 taken together form a 3- to 6-membered carbocyclic ring; R5 is hydrogen, C 1 ~C 3 Alkyl or NO 2 is an electron-withdrawing group comprising a CN group or a CN group, and r is an integer from 0 to 7. or a pharma- ceutically acceptable salt thereof.
2. A is optionally a heterocyclic or carbocyclic group selected from the group consisting of: [C7] During the ceremony, R is linear or branched (C 1 ~C 6 ) alkyl; L is a linker of formula (VI) where W is a group (Va') or (Vb'); [C8] PE is a dipeptide or tripeptide moiety consisting of any combination of the following amino acids: glycine, alanine, leucine, valine, citrulline, phenylalanine, the C-terminal amino acid residue being linked to W and the N-terminal amino acid residue being linked to RM; RM is a group selected from (VIa) to (VIc); [C9] During the ceremony, R3, R4 and R5 are hydrogen; r is preferably an integer from 3 to 5; A compound of formula (I) according to claim 1.
3. A is a heterocyclic group selected from the group consisting of (IIIa'), (IIIa"), (IIIb') and (IIIc'); W is a group (Va') or (Vb'); PE is a dipeptide or tripeptide selected from valine-alanine and valine-citrulline, phenylalanine-leucine-glycine; wherein the C-terminal amino acid residue is linked to W and the N-terminal amino acid residue is linked to RM; RM is a reactive moiety selected from group (VIa)-(VIc); A compound of formula (I) according to claim 2.
4. A is a heterocyclic group selected from the group consisting of (IIIa'), (IIIa"), (IIIb') and (IIIc'); L is a linker selected from the group consisting of (IVa) to (IVc): [C10] [wherein r is an integer from 3 to 5] A compound of formula (I) according to claim 3.
5. A compound of formula (I) according to claim 1 selected from the group consisting of: [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate (compound 1), [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate compound 2), [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate (compound 3), [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate (compound 4), [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate (compound 5), [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate (compound 6), [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate (compound 7), [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]amino]piperidine-1-carboxylate (compound 8); [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate (compound 9), [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]piperazine-1-carboxylate (compound 10); [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate (compound 11), [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl N-methyl-N-[1-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-4-piperidyl]carbamate (compound 12), [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-1,4-diazepane-1-carboxylate (compound 13), [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-6-imino-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-11-oxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-1,4-diazepane-1-carboxylate (compound 14), [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-1,4-diazepane-1-carboxylate (compound 15), and [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methyl-butanoyl]amino]propanoyl]amino]phenyl]methyl 4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl]-1,4-diazepane-1-carboxylate (compound 16).
6. Antibody-drug conjugate (ADC) of formula (Ia): [C11] [In the formula, Ab includes any entity, type or class of antibody that binds to, reactively associates with, or forms a complex with a receptor, antigen, or other receptive moiety associated with a given target cell population; m (drug loading) is an integer from 1 to 8; Ant-L is an anthracycline-linker reagent of formula (I) according to any one of claims 1 to 5, or a pharma- ceutically acceptable salt thereof.
7. The antibody-drug conjugate (ADC) of formula (Ia) according to claim 6, wherein Ant-L is a compound according to claim 5.
8. The antibody-drug conjugate (ADC) of formula (Ia) of claim 6, wherein Ab is an antibody that binds to one or more tumor-associated ErbB2 antigens or cell surface ErbB2 receptors.
9. Compound (Ia I ) to (Ia XVI 7. The antibody-drug conjugate (ADC) of formula (Ia) according to claim 6, selected from the group consisting of: [C12] [ka] [ka] [ka] [ka] [ka] [ka] [wherein m is an integer from 2 to 6, and TRZ is trastuzumab].
10. 7. A pharmaceutical composition comprising a mixture of antibody-drug conjugate compounds of formula (Ia) or pharma- ceutical acceptable salts thereof according to claim 6, wherein the average drug loading per antibody in the mixture of antibody-drug conjugate compounds is from about 2 to about 4.
11. 11. The pharmaceutical composition of claim 10, further comprising one or more chemotherapeutic agents.
12. An antibody-drug conjugate compound of formula (Ia) or a pharma- ceutically acceptable salt thereof according to claim 6 for use as a medicament.
13. 10. Use of an antibody-drug conjugate compound of formula (Ia) or a pharma- ceutically acceptable salt thereof according to claim 6 for the manufacture of a medicament for treating cancer.
14. 14. The use according to claim 13, wherein the cancer is selected from carcinomas, hematopoietic tumors of the lymphoid system, hematopoietic tumors of the myeloid system, tumors of mesenchymal origin including fibrosarcoma and rhabdomyosarcoma, tumors of the central and peripheral nervous system, and other tumors including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthomas, follicular thyroid carcinoma, Kaposi's sarcoma and mesothelioma.
15. 10. An antibody-drug conjugate compound of formula (Ia) or a pharma- ceutically acceptable salt thereof according to claim 6 for use in a method for treating cancer.
16. 16. The antibody-drug conjugate compound of formula (Ia) according to claim 15, wherein the cancer is selected from carcinomas, hematopoietic tumors of lymphoid system, hematopoietic tumors of myeloid system, tumors of mesenchymal origin including fibrosarcoma and rhabdomyosarcoma, tumors of the central and peripheral nervous system, and other tumors including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthomas, follicular thyroid carcinoma, Kaposi's sarcoma and mesothelioma.
17. A method of treating cancer comprising administering an effective amount of an antibody-drug conjugate of formula (Ia) according to claim 6 or a pharma- ceutically acceptable salt thereof.
18. 18. The method of claim 17, wherein the cancer is selected from carcinomas, hematopoietic tumors of the lymphoid system, hematopoietic tumors of the myeloid system, tumors of mesenchymal origin including fibrosarcoma and rhabdomyosarcoma, tumors of the central and peripheral nervous system, and other tumors including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthomas, follicular thyroid carcinoma, Kaposi's sarcoma, and mesothelioma.
19. 10. A pharmaceutical composition comprising a compound of formula (Ia) as defined in claim 6 or a pharma- ceutically acceptable salt thereof for treating cancer.
20. 20. The pharmaceutical composition of claim 19, wherein the cancer is selected from carcinomas, hematopoietic tumors of lymphoid system, hematopoietic tumors of myeloid system, tumors of mesenchymal origin including fibrosarcoma and rhabdomyosarcoma, tumors of the central and peripheral nervous system, and other tumors including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthomas, follicular thyroid carcinoma, Kaposi's sarcoma and mesothelioma.
21. An anthracycline-linker reagent compound of formula (I) according to claim 1, used as an intermediate for the preparation of an antibody-drug conjugate compound of formula (Ia) according to claim 6.
22. An anthracycline derivative of formula (II) selected from: [C13] or a pharma- ceutically acceptable salt thereof.
23. 23. An anthracycline derivative according to claim 22, for use as a synthetic intermediate for the preparation of an anthracycline-linker reagent compound of formula (I).
Citation Information
Patent Citations
Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
EP3636284A1
Anthracycline derivative conjugates, methods for preparing the same, and their uses as antitumor compounds.
JP2011528360A
Anthracycline disulfide intermediates, antibody-drug conjugates, and methods
JP2017531625A
Anthracycline-based antibody-drug conjugates with high in vivo tolerance
JP2020528069A
Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
WO2009099741A1
